Method for the detection of gene transcripts in blood and uses thereof

A method of identifying at least one potential marker for differentiating between different body states, the method comprising:

• for each gene of a set of genes,
• (a) determining a level of RNA encoded by the gene in blood samples of human subjects having a first body state, and a level of RNA encoded by the gene in blood samples of human subjects having a second body state, wherein the second body state is different from the first body state;
• and
• (b) comparing the levels with each other,
• wherein a determination, resulting from step (b), of a significant difference between the levels identifies the gene as a potential marker for differentiating between the first body state and the second body state, and
• wherein the set comprises the genes identified as:
• 100 kDa coactivator;
• 10 kD protein (BC10);
• 14-3-3 epsilon;
• 14-3-3 protein;
• 15 kDa selenoprotein (SEP15);
• 1-phosphatidylinositol-4-phosphate 5-kinase isoform C;
• 23 kD highly basic protein;
• 2-5A-dependent RNase;
• 2′-5′oligoadenylate synthetase 2 (OAS2);
• 26S proteasome subunit 11;
• 36 kDa phosphothyrosine protein;
• 3-phosphoglycerate dehydrogenase (PGAD);
• 3-prime-phosphoadenosine 5-prime-phosphosulfate synthase 1 (PAPSS1);
• 5-aminoimidazole-4-carboxamide ribonucleotide transformylase;
• 5′-nucleotidase;
• 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 (PFKFB4);
• 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PF2K);
• 71 kd heat shock cognate protein hsc70;
• 76 kDa membrane protein (P76);
• 8-oxoguanine DNA glycosylase (OGG1);
• a disintegrin and metalloprotease domain 10 (ADAM10);
• a disintegrin and metalloprotease domain 8 (ADAM8);
• A kinase anchor protein 95 (AKAP95);
• A kinase anchor protein, 149 kD (AKAP149);
• Absent in melanoma 1 (AIM1);
• accessory proteins BAP31/BAP29 (DXS1357E);
• acetyl-Coenzyme A acyltransferase (peroxisomal 3-oxoacyl-Coenzyme A thiolase) (ACAA);
• acetyl-Coenzyme A transporter (ACATN);
• acidic 82 kDa protein;
• acidic protein rich in leucines (SSP29);
• Aconitase 2, mitochondrial (ACO2);
• actin binding protein MAYVEN;
• actin, beta (ACTB);
• actin, gamma 1 (ACTG1);
• actin-binding LIM protein (ABLIM);
• Actinin, alpha 1 (ACTN1);
• actinin, alpha 4 (ACTN4);
• activated p21cdc42Hs kinase (ACK);
• activated RNA polymerase II transcription cofactor 4 (PC4);
• activating transcription factor 1 (ATF1);
• activating transcription factor 2 (ATF2);
• activating transcription factor 4 (tax-responsive enhancer element B67) (ATF4);
• active BCR-related gene (ABR);
• acyl-CoA oxidase (AOX);
• acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight chain (ACADM);
• acyl-Coenzyme A dehydrogenase, very long chain (ACADVL);
• acyloxyacyl hydrolase (neutrophil) (AOAH);
• adaptin, delta (ADTD);
• adaptin, gamma (ADTG);
• adaptor complex sigma3B (AP3S3);
• adaptor protein p150;
• adducin 1 (alpha) (ADD1);
• adducin 1 (alpha) (add1);
• adducin 3 (gamma) (ADD3);
• adenine nucleotide translocator 2 (fibroblast) (ANT2);
• adenine nucleotide translocator 3 (liver) (ANT3);
• adenomatous polyposis-coli protein (APC);
• adenosine deaminase, RNA-specific (ADAR);
• adenylate cyclase 3 (ADCY3);
• adenylate cyclase 7 (ADCY7);
• adenylate kinase 2 (AK2);
• adenylyl cyclase-associated protein (CAP);
• adipose differentiation-related protein;
• adipophilin (ADFP);
• ADP-ribosylation factor 1 (ARF1);
• ADP-ribosylation factor 3 (ARF3);
• ADP-ribosylation factor 4 (ARF4);
• ADP-ribosylation factor 5 (ARF5);
• ADP-ribosylation factor domain protein 1, 64 kD (ARFD1);
• ADP-ribosyltransferase (NAD+;
• poly (ADP-ribose) polymerase) (ADPRT);
• adrenergic, beta, receptor kinase 1 (ADRBK1);
• adrenoleukodystrophy-like 1 (ALDL1);
• AF-17;
• A-gamma-globin;
• A-gamma-globin (chromosome 11 allele);
• agammaglobulinaemia tyrosine kinase (ATK);
• AHNAK nucleoprotein (desmoyokin) (AHNAK);
• alanyl (membrane) aminopeptidase (aminopeptidase N, aminopeptidase M, microsomal aminopeptidase, CD13, p150) (ANPEP);
• alcohol dehydrogenase 5 (class III), chi polypeptide (ADH5);
• aldehyde dehydrogenase 1, soluble (ALDH1);
• aldehyde dehydrogenase 10 (fatty aldehyde dehydrogenase) (ALDH10);
• aldehyde reductase 1 (low Km aldose reductase) (ALDR1);
• aldo-keto reductase family 1, member A1 (aldehyde reductase) (AKR1A1);
• aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II) (AKR1C3);
• aldo-keto reductase family 7, member A2 (aflatoxin aldehyde reductase) (AKR7A2);
• aldolase A, fructose-bisphosphate (ALDOA);
• aldolase C, fructose-bisphosphate (ALDOC);
• alkaline phosphatase, liver/bone/kidney (ALPL);
• alpha mannosidase II isozyme;
• alpha thalassemia/mental retardation syndrome X-linked (ATRX);
• alpha-2 macroglobulin;
• alpha-2-globin;
• alpha-2-macroglobulin receptor/lipoprotein receptor protein (A2MR/LRP);
• alpha-polypeptide of N-acetyl-alpha-glucosaminidase (HEXA);
• alpha-spectrin;
• alpha-subunit of Gi2a (GTP-binding signal transduction protein);
• aminin receptor 1 (67 kD);
• Ribosomal protein SA (LAMR1);
• aminolevulinate, delta-, dehydratase (ALAD);
• amino-terminal enhancer of split (AES);
• amino-terminal enhancer of split (AES);
• AMP deaminase isoform L (AMPD2);
• amphiphysin (Stiff-Mann syndrome with breast cancer 128 kD autoantigen) (AMPH);
• amphiphysin II;
• amphiphysin-like (AMPHL);
• AMY-1;
• amyloid beta (A4) precursor protein-binding, family B, member 1 (Fe65) (APBB1);
• amyloid beta (A4) precursor-like protein 2 (APLP2);
• amyloid precursor protein (APP);
• annexin I (lipocortin I) (ANX1);
• annexin II;
• annexin II (lipocortin II;
• calpactin I, heavy polypeptide) (ANX2);
• annexin IV (placental anticoagulant protein II) (ANX4);
• annexin V (endonexin II) (ANX5);
• annexin V (endonexin II) (ANXV);
• annexin VI (p68) (ANX6);
• annexin VII (synexin) (ANX7);
• antigen identified by monoclonal antibodies 12E7, F21 and O13 (MIC2);
• antigen identified by monoclonal antibodies 4F2, TRA1.10, TROP4, and T43 (MDU1);
• anti-oxidant protein 2 (non-selenium glutathione peroxidase, acidic calcium-independent phospholipase A2) (KIAA0106);
• APEX nuclease (multifunctional DNA repair enzyme) (APEX);
• apoptosis inhibitor 1 (API1);
• apoptosis inhibitor 4 (survivin) (API4);
• apoptosis inhibitor 5 (API5);
• apoptosis specific protein (ASP);
• apoptotic protease activating factor (APAF1);
• aquaporin 3 (AQP3);
• aquaporin 9 (AQP9);
• arachidonate 12-lipoxygenase (ALOX12);
• arachidonate 5-lipoxygenase-activating protein (ALOX5AP);
• ariadne homolog (ARI);
• ariadne-2 (D. melanogaster) homolog (all-trans retinoic acid inducible RING finger) (ARI2);
• ARP1 (actin-related protein 1, yeast) homolog A (centractin alpha) (ACTR1A);
• ARP2 (actin-related protein 2, yeast) homolog (ACTR2);
• ARP2/3 protein complex subunit 34 (ARC34);
• Arp2/3 protein complex subunit p41 (ARC41);
• Arp2/3 protein complex subunit p16 (ARC16);
• Arp2/3 protein complex subunit p20 (ARC20);
• Arp2/3 protein complex subunit p21 (ARC21);
• ARP3 (actin-related protein 3, yeast) homolog (ACTR3);
• arrestin, beta 2 (ARRB2);
• arsA (bacterial) arsenite transporter, ATP-binding, homolog 1 (ASNA1);
• aryl hydrocarbon receptor nuclear translocator-like (ARNTL);
• aryl hydrocarbon receptor-interacting protein (AIP);
• arylsulfatase A (ARSA);
• asialoglycoprotein receptor 2 (ASGR2);
• asparaginyl-tRNA synthetase (NARS);
• aspartyl-tRNA synthetase (DARS);
• ataxia telangiectasia mutated (includes complementation groups A, C and D) (ATM);
• ataxin-2-like protein A2LP (A2LG);
• ATF6;
• ATP synthase (F1-ATPase) alpha subunit, mitochondrial;
• ATP synthase beta subunit gene;
• ATP synthase, H+ transporting, mitochondrial F0 complex, subunit b, isoform 1 (ATP5F1);
• ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c (subunit 9), isoform 1 (ATP5G1);
• ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit, isoform 1, cardiac muscle (ATP5A1);
• ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide (ATP5B);
• ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1 (ATP5C1);
• ATP synthase, H+ transporting, mitochondrial F1F0, subunit g (ATP5JG);
• ATP/GTP-binding protein (HEAB);
• ATPase, Ca++ transporting, ubiquitous (ATP2A3);
• ATPase, H+ transporting, lysosomal (vacuolar proton pump) 21kD (ATP6F);
• ATPase, H+ transporting, lysosomal (vacuolar proton pump) 31 kD (ATP6E);
• ATPase, H+ transporting, lysosomal (vacuolar proton pump) 42 kD;
• Vacuolar proton-ATPase, subunit C;
• V-ATPase, subunit C (ATP6D);
• ATPase, H+ transporting, lysosomal (vacuolar proton pump), alpha polypeptide, 70 kD, isoform 1 (ATP6A1);
• ATPase, H+ transporting, lysosomal (vacuolar proton pump), beta polypeptide, 56/58 kD, isoform 2 (ATP6B2);
• ATPase, H+ transporting, lysosomal (vacuolar proton pump), member J (ATP6J);
• ATPase, H+ transporting, lysosomal (vacuolar proton pump), subunit 1 (ATP6S1);
• ATP-binding cassette 50 (TNF-alpha stimulated) (ABC50);
• ATP-binding cassette protein M-ABC1 (mitochondrial);
• ATP-dependent RNA helicase;
• atrial natriuretic factor (ANF);
• autoantigen (Hs.75528);
• autoantigen (Hs.75682);
• autoantigen La/SS—B;
• axin (AXIN1);
• axonemal dynein heavy chain (DNAH17);
• basement membrane-induced gene (ICB1);
• basic leucine zipper nuclear factor 1 (JEM-1) (BLZF1);
• basic transcription factor 3 (BTF3);
• basigin (BSG);
• BC-2;
• B-cell CLL/lymphoma 6 (zinc finger protein 51) (BCL6);
• B-cell translocation gene 1, anti-proliferative (BTG);
• BCL2/adenovirus E1B 19 kD-interacting protein 2 (BNIP2);
• BCL2/adenovirus E1B 19 kD-interacting protein 3-like (BNIP3L);
• beclin 1 (coiled-coil, myosin-like BCL2-interacting protein) (BECN1);
• beta-1,2-N-acetylglucosaminyltransferase II (MGAT2);
• beta-2-microglobulin (B2M);
• beta-hexosaminidase alpha chain (HEXA);
• beta-tubulin;
• BING4;
• biphenyl hydrolase-like (serine hydrolase) (BPHL);
• bone marrow stromal cell antigen 1 (BST1);
• box-dependent myc-interacting protein isoform BIN1-10 (BIN1);
• brain my047 protein;
• branched chain keto acid dehydrogenase E1, alpha polypeptide (maple syrup urine disease) (BCKDHA);
• BRCA1 associated protein-1 (ubiquitin carboxy-terminal hydrolase) (BAP1);
• breakpoint cluster region protein, uterine leiomyoma, 1;
• barrier to autointegration factor (BCRP1);
• breakpoint cluster region protein, uterine leiomyoma, 2 (BCRP2);
• bromodomain-containing protein, 140 kD (peregrin) (BR140);
• Bruton's agammaglobulinemia tyrosine kinase (Btk);
• Bruton's tyrosine kinase (BTK);
• BS4;
• BTG2 (BTG2);
• BTK region clone ftp;
• BTK region clone ftp-3;
• BUB3 (budding uninhibited by benzimidazoles 3, yeast) homolog (BUB3);
• butyrate response factor 1 (EGF-response factor 1) (BRF1);
• butyrophilin (BTF1);
• butyrophilin like receptor;
• CAG repeat containing (CTG4A);
• CAGH32;
• calcium/calmodulin-dependent protein kinase (CaM kinase) II gamma (CAMK2G);
• calcium/calmodulin-dependent protein kinase (KIAA0787);
• calmodulin 1 (phosphorylase kinase, delta) (CALM1);
• calnexin (CANX);
• calpain, large polypeptide L1 (CAPN1);
• calpain, large polypeptide L2 (CANP2);
• calpain, small polypeptide (CAPN4);
• calpastatin (CAST);
• Calponin 2;
• calponin 2 (CNN2);
• calumenin (CALU);
• cAMP response element-binding protein CRE-Bpa (H_GS165L15.1);
• cAMP-dependent protein kinase type II (Ht31);
• canicular multispecific organic anion transporter (CMOAT2);
• capping protein (actin filament) muscle Z-line, alpha 1 (CAPZA1);
• capping protein (actin filament) muscle Z-line, alpha 2 (CAPZA2);
• capping protein (actin filament) muscle Z-line, beta (CAPZB);
• capping protein (actin filament), gelsolin-like (CAPG);
• carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD);
• carbonic anhydrase V, mitochondrial (CA5);
• carboxypeptidase D (CPD);
• cardiac beta-myosin heavy chain;
• carnitine/acylcarnitine translocase (CACT);
• Cas-Br-M (murine) ecotropic retroviral transforming sequence (cbl);
• casein kinase 1, alpha 1 (CSNK1A1);
• casein kinase 2, alpha 1 polypeptide (CSNK2A1);
• casein kinase I gamma 3L (CSNK1G3L);
• CASP8 and FADD-like apoptosis regulator (CFLAR);
• caspase 1, apoptosis-related cysteine protease (interleukin 1, beta, convertase) (CASP1);
• caspase 10, apoptosis-related cysteine protease (CASP10);
• caspase 3, apoptosis-related cysteine protease (CASP3);
• caspase 4, apoptosis-related cysteine protease (CASP4);
• caspase 5, apoptosis-related cysteine protease (CASP5);
• caspase 8, apoptosis-related cysteine protease (CASP8);
• caspase 9, apoptosis-related cysteine protease (CASP9);
• catalase (CAT);
• catechol-O-methyltransferase (COMT);
• catenin (cadherin-associated protein), alpha 1 (102 kD) (CTNNA1);
• cathelicidin antimicrobial peptide (CAMP);
• cathepsin B (CTSB);
• cathepsin C (CTSC);
• cathepsin D (lysosomal aspartyl protease) (CTSD);
• cathepsin E (CTSE);
• cathepsin G (CTSG);
• cathepsin S (CTSS);
• cathepsin W (lymphopain) (CTSW);
• CCAAT/enhancer binding protein (C/EBP), alpha (CEBPA);
• CCAAT/enhancer binding protein (C/EBP), delta (CEBPB);
• CCAAT-box-binding transcription factor (CBF2);
• CD14 antigen (CD14);
• CD1C antigen, c polypeptide (CD1C);
• CD2 antigen (cytoplasmic tail)-binding protein 2 (CD2BP2);
• CD2 antigen (p50), sheep red blood cell receptor (CD2);
• CD2 cytoplasmic tail-binding protein 1 (CD2BP1);
• CD20 antigen (CD20);
• CD20 receptor (S7);
• CD22 antigen (CD22);
• CD24 signal transducer;
• CD33 antigen (gp67) (CD33);
• CD33 antigen-like 2;
• CD36 antigen (collagen type I receptor, thrombospondin receptor) (CD36);
• CD37 antigen (CD37);
• CD38 alt;
• CD39 antigen (CD39);
• CD3D antigen, delta polypeptide (TiT3 complex) (CD3D);
• CD3E antigen, epsilon polypeptide (TiT3 complex) (CD3E);
• CD3G antigen, gamma polypeptide (TiT3 complex) (CD3G);
• CD3Z antigen, zeta polypeptide (TiT3 complex) (CD3Z);
• CD3-zeta (clone pBS NK1);
• CD4 antigen (p55) (CD4);
• CD44 antigen (homing function and Indian blood group system (CD44);
• CD48 antigen (B-cell membrane protein) (CD48);
• CD53 antigen (CD53);
• CD63 antigen (melanoma 1 antigen) (CD63);
• CD68 antigen (CD68);
• CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated) (CD74);
• CD79A antigen (immunoglobulin-associated alpha) (CD79A);
• CD79B antigen (immunoglobulin-associated beta) (CD79B);
• CD8 antigen, alpha polypeptide (p32) (CD8A);
• CD8 antigen, beta polypeptide 1 (p37) (CD8B1);
• CD81 antigen (target of antiproliferative antibody 1 (CD81);
• CD84 antigen (leukocyte antigen) (CD84);
• CD86 antigen;
• CD9 antigen (p24) (CD9);
• CD97 antigen (CD97);
• CDC23 (cell division cycle 23, yeast, homolog) (CDC23);
• CDC37 homolog;
• Cdc42 effector protein 3 (CEP3);
• CDC-like kinase (CLK);
• CDC-like kinase 2 (CLK2);
• CDW52 antigen (CAMPATH-1 antigen) (CDW52);
• cell cycle progression restoration 8 protein (CPR8);
• cell division cycle 10 (homologous to CDC10 of S. cerevisiae) (CDC10);
• cell division cycle 20, S. cerevisiae homolog (CDC20);
• cell division cycle 25B (CDC25B);
• cell division cycle 42 (GTP-binding protein, 25 kD) (CDC42);
• centromere protein B (80 kD) (CENPB);
• cep250 centrosome associated protein;
• ceroid-lipofuscinosis, neuronal 2, late infantile (Jansky-Bielschowsky disease) (CLN2);
• CGI-19 protein;
• chaperonin containing TCP1, subunit 3 (gamma) (CCT3);
• chaperonin containing TCP1, subunit 4 (delta) (CCT4);
• chaperonin containing TCP1, subunit 6A (zeta 1) (CCT6A);
• chaperonin containing TCP1, subunit 7 (eta) (CCT7);
• Chediak-Higashi syndrome 1 (CHS1);
• chemokine (C—C motif) receptor 2 (CCR2);
• chemokine (C—C motif) receptor 7 (CCR7);
• chemokine (C—X3-C) receptor 1 (CX3CR1);
• chemokine (C—X—C motif), receptor 4 (fusin) (CXCR4);
• chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1);
• chitinase 3-like 2 (CHI3L2);
• chloride channel 6 (CLCN6);
• Chloride intracellular channel 1 (CLIC1);
• chondroitin sulfate proteoglycan 2 (versican) (CSPG2);
• chondroitin sulfate proteoglycan core protein;
• chromodomain helicase DNA binding protein 1 (CHD1);
• chromodomain helicase DNA binding protein 1-like (CHD1L);
• chromodomain helicase DNA binding protein 2 (CHD2);
• chromodomain helicase DNA binding protein 3 (CHD3);
• chromodomain helicase DNA binding protein 4 (CHD4);
• chromosome 1 open reading frame 7 (C1ORF7);
• chromosome 1 specific transcript KIAA0493;
• chromosome 17 open reading frame 1B (C17ORF1B);
• chromosome 4 open reading frame 1 (C4ORF1);
• chromosome condensation 1-like (CHC1L);
• chromosome X open reading frame 5 (CXORF5);
• chromosome-associated polypeptide C (CAP-C);
• cig42;
• cig5;
• citrate synthase (CS);
• class I major histocompatibility antigen (HLA-Cw3);
• clathrin assembly protein lymphoid myeloid leukemia (CALM);
• clathrin heavy chain;
• clathrin, heavy polypeptide-like 2 (CLTCL2);
• clathrin-associated/assembly/adaptor protein, medium 1 (CLAPM1);
• cleavage stimulation factor, 3′ pre-RNA, subunit 3, 77 kD (CSTF3);
• clk3;
• clone 23815 (Hs.82845);
• clone 24592 mRNA sequence;
• Clq/MBL/SPA receptor C1qR (p);
• clusterin (complement lysis inhibitor, SP-40,40, sulfated glycoprotein 2, testosterone-repressed prostate message 2, apolipoprotein J) (CLU);
• CMP-sialic acid transporter (CMPST);
• CMRF35;
• c-myc oncogene containing coxIII;
• coagulation factor II (thrombin) receptor (F2R);
• coagulation factor V (proaccelerin, labile factor) (F5);
• coagulation factor XIII a subunit;
• coagulation factor XIII, A1 polypeptide (F13A1);
• coated vesicle membrane protein (RNP24);
• coatomer protein complex, subunit alpha (COPA);
• Cofilin 1 (non-muscle) (CFL1);
• cold inducible RNA-binding protein (CIRBP);
• cold shock domain protein A (CSDA);
• collagen, type IX, alpha 2 (COL9A2);
• colony stimulating factor 1 receptor, formerly McDonough feline sarcoma viral (v-fins) oncogene homolog (CSF1R);
• colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage) (CSF2RB);
• colony stimulating factor 3 receptor (granulocyte) (CSF3R);
• complement component 5 receptor 1 (C5a ligand) (C5R1);
• conserved gene amplified in osteosarcoma (OS4);
• COP9 (constitutive photomorphogenic, Arabidopsis, homolog) subunit 3 (COPS3);
• COP9 homolog (HCOP9);
• COPII protein, homolog of S. cerevisiae SEC23p (SEC23A);
• copine I (CPNE1);
• coproporphyrinogen oxidase (coproporphyria, harderoporphyria) (CPO);
• core-binding factor, beta subunit (CBFB);
• coronin;
• cot (cancer Osaka thyroid) oncogene (COT);
• cryptochrome 1 (photolyase-like) (CRY1);
• CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) phosphatase, subunit 1 (CTDP1);
• C-terminal binding protein 1 (CTBP1);
• C-terminal binding protein 2 (CTBP2);
• CUG triplet repeat, RNA-binding protein 1 (CUGBP1);
• cullin 1 (CUL1);
• cullin 3 (CUL3);
• cut (Drosophila)-like 1 (CCAAT displacement protein) (CUTL1);
• cyclin D2 (CCND2);
• cyclin D3 (CCND3);
• cyclin G1 (CNNG1);
• cyclin I;
• cyclin T2 (CNNT2);
• cyclin-dependent kinase 2 (CDK2);
• cyclin-dependent kinase inhibitor (p27Kip1);
• cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A);
• cystatin B (stefin B) (CSTB);
• cysteine and glycine-rich protein 3 (cardiac LIM protein) (CSRP3);
• cytidine deaminase (CDA);
• cytochrome b (−245) beta chain N-terminal region X-linked granulomatous disease gene);
• cytochrome b-245, beta polypeptide (chronic granulomatous disease) (CYBB);
• cytochrome c oxidase subunit IV (COX4);
• cytochrome c oxidase subunit Vb (COX5B);
• cytochrome c oxidase subunit VII-related protein (COX7RP);
• cytokine suppressive anti-inflammatory drug binding protein 1 (p38 MAP kinase) (CSBP1);
• Cytoplasmic antiproteinase=38 kda intracellular serine proteinase inhibitor;
• cytotoxic granule-associated RNA-binding protein p40-TIA-1;
• D123 (D123);
• D2-2;
• D38;
• damage-specific DNA binding protein 1 (127 kD) (DDB1);
• DEAD/H (Asp-Glu-Ala-Asp/His) box binding protein 1 (DDXBP1);
• DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide (72 KD) (P72);
• DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 1 (DDX1);
• DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 15 (DDX15);
• DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 16 (DDX16);
• DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 3 (DDX3);
• DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 5 (RNA helicase, 68 kD) (DDX5);
• DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 6 (RNA helicase, 54 kD) (DDX6);
• DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 8 (RNA helicase, 54 kD) (DDX8);
• DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 9 (RNA helicase A, nuclear DNA helicase II;
• leukophysin) (DDX9);
• DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide, Y chromosome (DBY);
• Death associated protein 3 (DAP3);
• death effector domain-containing protein (DEDD);
• death-associated protein 6 (DAXX);
• dedicator of cyto-kinesis 2 (DOCK2);
• defender against cell death 1 (DAD1);
• Defensin, alpha 1, myeloid-related sequence (DEFA1);
• DEK gene (D6S231E);
• delta sleep inducing peptide, immunoreactor (DSIPI);
• dendritic cell protein (GA17);
• deoxycytidine kinase (DCK);
• deoxyribonuclease II, lysosomal (DNASE2);
• DGS-I;
• diacylglycerol kinase;
• diacylglycerol kinase alpha (DAGK1) (clone 24);
• diaphanous (Drosophila, homolog) 1 (DIAPH1);
• diaphorase (NADH) (cytochrome b-5 reductase) (DIA1);
• differentiated Embryo Chondrocyte expressed gene 1 (DEC1);
• differentiation antigen CD20;
• DiGeorge syndrome critical region gene 2 (DGCR2);
• dihydrolipoamide dehydrogenase (E3 component of pyruvate dehydrogenase complex, 2-oxo-glutarate complex, branched chain keto acid dehydrogenase complex) (DLD);
• dihydrolipoamide S-acetyltransferase (E2 component of pyruvate dehydrogenase complex) (DLAT);
• dihydropyrimidinase-like 2 (DPYSL2);
• dinG gene;
• diptheria toxin resistance protein required for diphthamide biosynthesis (Saccharomyces)-like 2 (DPH2L2);
• DJ-1 protein;
• Dmx-like 1 (DMXL1);
• DNA (cytosine-5-)-methyltransferase 1 (DNMT1);
• DNA fragmentation factor, 40 kD, beta subunit (DFFB);
• DNA fragmentation factor, 45 kD, alpha subunit (DFFA);
• DNA mismatch repair protein (hMLH1);
• DNA segment on chromosome X (unique) 648 expressed sequence;
• DNA segment, single copy probe LNS-CAI/LNS-CAII (deleted in polyposis (D5S346);
• DnaJ protein;
• docking protein 2, 56 kD (DOK2);
• dolichyl-diphosphooligosaccharide-protein glycosyltransferase (DDOST);
• dolichyl-phosphate mannosyltransferase polypeptide 1, catalytic subunit (DPM1);
• down-regulated by activation (immunoglobulin superfamily) (DORA);
• D-type cyclin-interacting protein 1 (DIP1);
• dual specificity phosphatase 1 (DUSP1);
• dual specificity phosphatase 11 (RNA/RNP complex 1-interacting) (dusp11);
• dual specificity phosphatase 3 (vaccinia virus phosphatase VH1-related) (DUSP3);
• dual specificity phosphatase 6 (DUSP6);
• dynactin 1 (p150, Glued (Drosophila) homolog) (DYTN1);
• dynamin 2 (DNM2);
• dynein, cytoplasmic, light intermediate polypeptide 2 (DNCLI2);
• dyskeratosis congenita 1, dyskerin (DKC1);
• dystonia 1, torsion (autosomal dominant) (DYT1);
• dystrobrevin, beta (DTNB);
• dystrophia myotonica-containing WD repeat motif (DMWD);
• dystrophia myotonica-protein kinase (DMPK);
• E1B-55 kDa-associated protein;
• E2F transcription factor 3 (E2F3);
• E2F transcription factor 4, p107/p130-binding (E2F4);
• E2F transcription factor 5, p130-binding (E2F5);
• E74-like factor 1 (ets domain transcription factor) (ELF1);
• E74-like factor 4 (ets domain transcription factor) (ELF4);
• early development regulator 2 (homolog of polyhomeotic 2) (EDR2);
• EBV induced G-protein coupled receptor (EBI2);
• ecotropic viral integration site 2B (EVI2B);
• ectin, galactoside-binding, soluble, 1 (galectin 1) (LGALS1);
• EGF-like-domain, multiple 4 (EGFL4);
• eIF-2-associated p67 homolog;
• elav-type RNA-binding protein (ETR-3);
• electron-transfer-flavoprotein, alpha polypeptide (glutaric aciduria II) (ETFA);
• ELK3, ETS-domain protein (SRF accessory protein 2) (ELK3);
• elongation factor 1-beta;
• elongation factor Ts (mitochondrial protein);
• elongation factor Tu-nuclear encoded mitochondrial;
• eMDC II protein;
• ems1 sequence (mammary tumor and squamous cell carcinoma-associated (p80/85 src substrate) (EMS1);
• endogenous retroviral element HC2;
• endosulfine alpha (ENSA);
• endothelial differentiation, sphingolipid G-protein-coupled receptor, 1 (EDG1);
• endothelial monocyte-activating polypeptide (EMAPII);
• enolase 1, (alpha) (ENO1);
• enolase 2, (gamma, neuronal) (ENO2);
• enolase-alpha;
• enoyl Coenzyme A hydratase 1, peroxisomal (ECH1);
• enoyl Coenzyme A hydratase, short chain, 1, mitochondrial (ECHS1);
• epidermal growth factor receptor pathway substrate 15 (EPS15);
• epithelial membrane protein 3 (EM[P3);
• Epoxide hydrolase 1, microsomal (xenobiotic) (EPHX1);
• ERF-2;
• ERp28 protein;
• erythrocyte membrane protein;
• erythroleukemic cells K562;
• EST (Hs.189509);
• estrogen receptor-related protein (hERRa1);
• ET binding factor 1 (SBF1);
• ets domain protein ERF;
• eukaryotic translation elongation factor 1 alpha 1 (EEF1A1);
• eukaryotic translation elongation factor 1 beta 2 (EEF1B2);
• eukaryotic translation elongation factor 1 delta (guanine nucleotide exchange protein) (EEF1D);
• eukaryotic translation elongation factor 1 gamma (EEF1G);
• eukaryotic translation elongation factor 2 (EEF2);
• eukaryotic translation initiation factor 2, subunit 1 (alpha, 35 kD) (EIF2S1);
• eukaryotic translation initiation factor 2, subunit 2 (beta, 38 kD) (EIF2S2);
• eukaryotic translation initiation factor 2, subunit 3 (gamma, 52 kD) (EIF2S3);
• eukaryotic translation initiation factor 3, subunit 10 (theta, 150/170 kD) (EIF3S10);
• eukaryotic translation initiation factor 3, subunit 2 (beta, 36 kD) (EIF3S2);
• eukaryotic translation initiation factor 3, subunit 3 (gamma, 40 kD) (EIF3S3);
• eukaryotic translation initiation factor 3, subunit 4 (delta, 44 kD) (EIF3S4);
• eukaryotic translation initiation factor 3, subunit 6 (48 kD) (EIF3S 6);
• eukaryotic translation initiation factor 3, subunit 6 (EIF3S6);
• eukaryotic translation initiation factor 3, subunit 7 (zeta, 66/67 kD) (EIF3S7);
• eukaryotic translation initiation factor 3, subunit 8, 110 KD (EIF3S 8);
• eukaryotic translation initiation factor 4 gamma, 1 (EIF4G);
• eukaryotic translation initiation factor 4 gamma, 1 (EIF4G1);
• eukaryotic translation initiation factor 4 gamma, 2 (EIF4G2);
• eukaryotic translation initiation factor 4 gamma, 2 (EIFG2);
• eukaryotic translation initiation factor 4A, isoform 1 (EIF4A 1);
• eukaryotic translation initiation factor 4A, isoform 2 (EIF4A2);
• eukaryotic translation initiation factor 4B (EIF4B);
• Eukaryotic translation initiation factor 4E binding protein 2 (EIF4EBP2);
• eukaryotic translation initiation factor 5 (EIF5);
• eukaryotic translation termination factor 1 (ETF1);
• EV12 protein;
• Ewing sarcoma breakpoint region 1 (EWSR1);
• EWS/FLI1 activated transcript 2 homolog (EAT-2);
• EWS-E1A-F chimeric protein;
• excision repair cross-complementing rodent repair deficiency, complementation group 1 (includes overlapping antisense sequence) (ERCC1);
• excision repair cross-complementing rodent repair deficiency, complementation group 5 (xeroderma pigmentosum, complementation group G (Cockayne syndrome)) (ERCC5);
• exostoses (multiple)-like 3 (EXTL3);
• F11;
• F1-ATPase beta subunit (F-1 beta);
• Fanconi anaemia group A;
• Fanconi anemia, complementation group A (FANCA);
• far upstream element (FUSE) binding protein 1 (FUBP1);
• farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase) (FDPS);
• farnesyl-diphosphate farnesyltransferase 1 (FDFT1);
• farnesyltransferase, CAAX box, beta (FNTB);
• Fas-ligand associated factor 1;
• fatty-acid-Coenzyme A ligase, long-chain 1 (FACL1);
• Fc fragment of IgA, receptor for (FCAR);
• Fc fragment of IgE, high affinity I, receptor for;
• gamma polypeptide (FCER1G);
• Fc fragment of IgE, low affinity II, receptor for (CD23A) (FCER2);
• Fc fragment of IgG, low affinity IIa, receptor for (CD32);
• Fc fragment of IgG, low affinity IIa, receptor for (CD32) (FCGR2A);
• Fc fragment of IgG, low affinity IIIa, receptor for (CD16) (FCGR3A);
• Fc fragment of IgG, receptor, transporter, alpha (FCGRT);
• fc-fgr;
• Fc-gamma-receptorIIIB (FCGR3B);
• feline sarcoma (Snyder-Theilen) viral (v-fes)/Fujinami avian sarcoma (PRCII) viral (v-fps) oncogene homolog (FES) c-fes/fps);
• female sterile homeotic-related gene 1 (mouse homolog) (FSRG1);
• ferritin L-chain;
• ferritin, heavy polypeptide 1 (FTH1);
• fetal Alzheimer antigen (FALZ);
• fetal Ig heavy chain variable region;
• fibrillarin (FBL);
• fibrinogen-like protein 2 (T49);
• ficolin (collagen/fibrinogen domain-containing) 1 (FCN1);
• filamin A, alpha (actin-binding protein-280) (FLNA);
• filamin B, beta (actin-binding protein-278) (FLNB);
• Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously expressed (fox derived);
• ribosomal protein S30 (FAU);
• FK-506 binding protein;
• FK506-binding protein 1A (12 kD) (FKBP1A);
• FK506-binding protein 1B (12.6 kD) (FKBP1B);
• FK506-binding protein 5 (FKBP5);
• Flightless I (Drosophila) homolog (FLII);
• FLN29 (FLN29);
• flotillin 2 (FLOT2);
• folate receptor 2 (fetal) (FOLR2);
• forkhead (Drosophila) homolog (rhabdomyosarcoma) like 1 (FKHRL1);
• Formyl peptide receptor 1 (FPR1);
• formyl peptide receptor-like 1 (FPRL1);
• fragile X mental retardation 1 (FMR1);
• fragile X mental retardation, autosomal homolog 1 (FXR1);
• Friend leukemia virus integration 1 (FLI1);
• fructose-bisphosphatase 1 (FBP1);
• FSHD-associated repeat DNA, proximal region;
• fucose-1-phosphate guanylyltransferase (FPGT);
• full length insert cDNA clone ZA78A09;
• full length insert cDNA YP07G10;
• fumarate hydratase (FH);
• FYN-binding protein (FYB-120/130) (FYB);
• G protein beta subunit-like protein 12.3;
• G protein-coupled receptor kinase 6 (GPRK6);
• G1 to S phase transition 1 (GSPT1);
• GA-binding protein transcription factor, beta subunit 2 (47 kD) (GABPB2);
• galactose-1-phosphate uridylyltransferase (GALT);
• galactosidase, beta 1 (GLB1);
• galectin-9 isoform;
• gamma2-adaptin (G2AD);
• gamma-actin;
• gamma-aminobutyric acid (GABA) B receptor 1 (GABBR1);
• GATA-binding protein 2 (GATA2);
• GATA-binding protein 3 (GATA3);
• GCN5 (general control of amino-acid synthesis, yeast, homolog)-like 1 (GCN5L1);
• GDP dissociation inhibitor 1 (GDI1);
• GDP dissociation inhibitor 2 (GCI2);
• GDS-related protein (HKE1.5);
• gelsolin (amyloidosis, Finnish type) (GSN);
• general transcription factor II, I (GTF2I);
• general transcription factor II, i, pseudogene 1 (GTF2IP1);
• general transcription factor IIF, polypeptide 1 (74 kD subunit) (GTF2F1);
• general transcription factor IIH, polypeptide 3 (34 kD subunit) (GTF2H3);
• general transcription factor IIH, polypeptide 4 (52 kD subunit) (GTF2H4);
• general transcription factor IIIA (GTF3A);
• general transcription factor IIIC, polypeptide 1 (alpha subunit, 220 kD) (GTF3C1);
• general transcription factor IIIC, polypeptide 2 (beta subunit, 110 kD) (GTF3C2);
• germline immunoglobulin heavy chain (IGHV@);
• germline immunoglobulin heavy chain, variable region;
• germline immunoglobulin heavy chain, variable region, (21-2);
• GLE1 (yeast homolog)-like, RNA export mediator (GLE1L);
• glia maturation factor, beta (GMFB);
• glioma-associated oncogene homolog (zinc finger protein) (GLI);
• globin, alpha 2;
• glucocorticoid receptor (GRL);
• glucose phosphate isomerase (CONTAINS LARGE REPEAT);
• glucosamine (N-acetyl)-6-sulfatase (Sanfilippo disease IIID) (GNS);
• glucose transporter-like protein-III (GLUT3);
• glucosidase, alpha;
• acid (Pompe disease, glycogen storage disease type II) (GAA);
• glucosidase, beta;
• acid (includes glucosylceramidase) (GBA);
• glutamate dehydrogenase 1 (GLUD1);
• glutamate-ammonia ligase (glutamine synthase) (GLUL);
• glutamate-cysteine ligase (gamma-glutamylcysteine synthetase), catalytic (72.8 kD) (GLCLC);
• glutamine cyclotransferase;
• glutamine-fructose-6-phosphate transaminase 1 (GFPT1);
• glutaminyl-tRNA synthetase;
• glutaminyl-tRNA synthetase (QARS);
• glutamyl-prolyl-tRNA synthetase (EPRS);
• glutathione peroxidase 1 (GPX1);
• glutathione peroxidase 4 (phospholipid hydroperoxidase) (GPX4);
• glutathione S-transferase pi (GSTP1);
• glutathione S-transferase subunit 13 homolog;
• glyceraldehyde-3-phosphate dehydrogenase (GAPD);
• glycogenin (GYG);
• glycophorin C (Gerbich blood group) (GYPC);
• glycoprotein M6B (GPM6B);
• glycyl-tRNA synthetase (GARS);
• glyoxalase I (lactoyl glutathione lyase) (GLYI);
• golgi autoantigen, golgin subfamily a, 1 (GOLGA1);
• golgi autoantigen, golgin subfamily a, 4 (GOLGA4);
• golgi autoantigen, golgin subfamily b, macrogolgin (with transmembrane signal), 1 (GOLGB1);
• gp25L2 protein;
• grancalcin;
• granulin (GRN);
• Granulysin (NKG5);
• granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3) (GZMA);
• GRB2-related adaptor protein (GRAP);
• Grb2-related adaptor protein 2 (GRAP2);
• GRO1 oncogene (melanoma growth stimulating activity, alpha) (GRO1);
• growth arrest and DNA-damage-inducible gene (GADD153);
• growth arrest-specific 7 (GAS7);
• growth factor receptor-bound protein 2 (GRB2);
• GS1 (protein of unknown function);
• GS3955;
• GTP binding protein 1 (GTPBP1);
• GTPase activating protein-like (GAPL);
• Gu protein (GURDB);
• guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2 (GNAI2);
• guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 3 (GNAI3);
• guanine nucleotide binding protein (G protein), alpha stimulating activity polypeptide 1 (GNAS1);
• guanine nucleotide binding protein (G protein), alpha transducing activity polypeptide 2 (GNAT2);
• guanine nucleotide binding protein (G protein), beta 5 (GNB5);
• guanine nucleotide binding protein (G protein), beta polypeptide 1 (GNB1);
• guanine nucleotide binding protein (G protein), q polypeptide (GNAQ);
• guanine nucleotide binding protein-like 1 (GNL1);
• guanine nucleotide exchange factor;
• guanine nucleotide regulatory factor (LFP40);
• GUANINE-MONOPHOSPHATE SYNTHETASE (GMPS);
• guanosine-diphosphatase like protein;
• guanylate binding protein 1, interferon-inducible, 67 kD (GBP1);
• guanylate binding protein 2, interferon-inducible (GBP2);
• H2A histone family, member C (H2AFC);
• H2A histone family, member Y (H2AY);
• H2B histone family, member L (H2BFL);
• h2-calponin;
• H-2K binding factor-2;
• H3 histone family, member K (H3FK);
• H3 histone, family 3A (H3F3A);
• H3 histone, family 3B (H3.3B) (H3F3B);
• hbc647;
• heat shock 27 kD protein 1 (HSPB1);
• heat shock 40 kD protein 1 (HSPF1);
• heat shock 60 kD protein 1 (chaperonin) (HSPD1);
• heat shock 70 kD protein 1 (HSPA1A);
• heat shock 70 kD protein 5 (glucose-regulated protein, 78 kD) (HSPA5);
• heat shock 70 kD protein 6 (HSP70B′) (HSPA6);
• heat shock 70 kD protein 9B (mortalin-2) (HSPA9B);
• heat shock factor binding protein 1 (HSBP1);
• heat shock protein 90;
• heat shock protein, DNAJ-like 2 (HSJ2);
• Hect (homologous to the E6-AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1 (HERC1);
• hect domain and RLD 2 (HERC2);
• helicase-like protein (HLP);
• helix-loop-helix protein HE47 (E2A);
• hematopoietic cell-specific Lyn substrate 1 (HCLS1);
• heme oxygenase (decycling) 1 (HMOX1);
• hemoglobin beta (beta globin);
• hemoglobin, alpha 1 (HBA1);
• hemoglobin, beta (HBB);
• emokine (C—X—C motif), receptor 4 (fusin) (CXCR4);
• hemopoietic cell kinase (HCK);
• hepatitis C-associated microtubular aggregate protein p44;
• hepatoma-derived growth factor;
• Hermansky-Pudlak syndrome (HPS);
• heterogeneous nuclear ribonucleoprotein (C1/C2) (HNRPC);
• heterogeneous nuclear ribonucleoprotein A/B (HNRPAB);
• heterogeneous nuclear ribonucleoprotein A1 (HNRPA1);
• heterogeneous nuclear ribonucleoprotein A2/B1 (HNRPA2B1);
• heterogeneous nuclear ribonucleoprotein D (hnRNP D);
• heterogeneous nuclear ribonucleoprotein D-like (HNRPDL);
• heterogeneous nuclear ribonucleoprotein F (HNRPF);
• heterogeneous nuclear ribonucleoprotein G (HNRPG);
• heterogeneous nuclear ribonucleoprotein H1 (H) (HNRPH1);
• heterogeneous nuclear ribonucleoprotein K (HNRPK);
• heterogeneous nuclear ribonucleoprotein R (HNRPR);
• heterogeneous nuclear ribonucleoprotein U (scaffold attachment factor A) (HNRPU);
• hexokinase 1 (HK1);
• hexokinase 2 (HK2);
• hexokinase 3 (HK3);
• hexosaminidase A (alpha polypeptide) (HEXA;
• HGMP07I gene for olfactory receptor;
• High density lipoprotein binding protein (HDLBP);
• high-mobility group (nonhistone chromosomal) protein 1 (HMG1);
• High-mobility group (nonhistone chromosomal) protein 17 (HMG17);
• high-mobility group (nonhistone chromosomal) protein 2 (HMG2);
• high-mobility group (nonhistone chromosomal) protein isoforms I and Y;
• histidine ammonia-lyase (HAL);
• histidyl-tRNA synthetase (HARS);
• histocompatibility antigen (HLA-Cw3), class I;
• histone deacetylase 1 (HDAC);
• histone deacetylase 1 (HDAC1);
• histone deacetylase 5 (NY—CO-9);
• HK2 gene for hexokinase II;
• HL9 monocyte inhibitory receptor precursor;
• HLA class I heavy chain (HLA-Cw*1701);
• HLA class I locus C heavy chain;
• HLA class II SB 4-beta chain;
• HLA class III region containing NOTCH4 gene;
• HLA-A;
• HLA-A*7402;
• HLA-A11;
• HLA-B;
• HLA-B associated transcript-1 (D6S81E);
• HLA-B associated transcript-2 (D6S51E);
• HLA-B*1529;
• HLA-Bw72 antigen;
• HLA-C gene (HLA-Cw*0701 allele);
• HLA-Cw*0701;
• HLA-Cw*0801;
• HLA-Cw*1203;
• HLA-DR alpha-chain;
• HLA-F (leukocyte antigen F);
• HMG box containing protein 1;
• Hmob33;
• HMT1 (hnRNP methyltransferase, S. cerevisiae)-like 1 (HRMT1L1);
• homeodomain-interacting protein kinase 3 (HIPK3);
• homolog of Drosophila past (PAST);
• homolog of yeast (S. cerevisiae) ufd2 (UFD2);
• HPV16 E1 protein binding protein;
• HRIHFB2157;
• hsc70 gene for 71 kd heat shock cognate protein;
• HSPC012;
• HSPC021;
• HsPex13p;
• htra2-beta-2;
• HU—K4;
• hunc18b2;
• HUNKI;
• huntingtin-interacting protein HYPA/FBP11 (HYPA);
• hVps41p (HVPS41);
• hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A hydratase (trifunctional protein), alpha subunit (HADHA);
• hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A hydratase (trifunctional protein), beta subunit (HADHB);
• hydroxysteroid (17-beta) dehydrogenase 1 (HSD17B1);
• hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) (HIF1A);
• Ia-associated invariant gamma-chain (clones lambda-y (1,2,3));
• iduronate 2-sulfatase (Hunter syndrome) (IDS);
• Ig heavy chain variable region;
• Ig heavy chain variable region (VH4DJ) (clone T14.4);
• Ig heavy chain variable region (VH4DJ) (clone T22.18);
• Ig J chain;
• Ig kappa;
• IG kappa light chain variable region A20;
• Ig lambda light chain variable region (26-34ITIIIF120);
• Ig mu-chain VDJ4-region;
• Ig rearranged anti-myelin kappa-chain (V-J4-region, hybridoma AE6-5);
• Ig rearranged H-chain mRNA V-region;
• IgG Fc binding protein (FC(GAMMA)BP);
• IgG heavy chain variable region (vH26);
• IgM heavy chain (C mu, membrane exons);
• IkB kinase-beta (IKK-beta);
• IL-1 receptor type II;
• IL2-inducible T-cell kinase (ITK);
• immediate early protein (ETR101);
• immunogloblin light chain (lambda);
• Immunoglobulin (CD79A) binding protein 1 (IGBP1);
• immunoglobulin G Fc receptor IIIB;
• immunoglobulin gamma 3 (Gm marker) (IGHG3);
• immunoglobulin heavy chain (VI-3B);
• immunoglobulin heavy chain J region;
• immunoglobulin heavy chain J region, B1 haplotype;
• immunoglobulin heavy chain variable region (IGH) (clone 21u-48);
• immunoglobulin heavy chain variable region (IGH) (clone 23u-1);
• immunoglobulin heavy chain variable region V3-43 (IGHV@);
• immunoglobulin heavy chain variable region V3-7 (IGHV@);
• immunoglobulin IgH heavy chain Fd fragment;
• immunoglobulin kappa light chain;
• immunoglobulin kappa light chain V-segment A27;
• immunoglobulin light chain;
• immunoglobulin light chain variable region (lambda IIIb subgroup) from IgM rheumatoid factor;
• immunoglobulin M heavy chain V region=anti-lipid A antibody;
• immunoglobulin mu (IGHM);
• immunoglobulin mu binding protein 2 (IGHMBP2);
• immunoglobulin superfamily, member 2 (IGSF2);
• imogen 38 (IMOGEN38);
• IMP (inosine monophosphate) dehydrogenase 1 (IMPDH1);
• IMP (inosine monophosphate) dehydrogenase 2 (IMPDH2);
• inc finger protein 151 (pHZ-67) (ZNF151);
• inc finger protein, C2H2, rapidly turned over (ZNF20);
• inducible poly(A)-binding protein (IPABP);
• inducible protein (Hs.80313);
• inhibitor of DNA binding 2, dominant negative helix-loop-helix protein (ID2);
• inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein (IKBKAP);
• inositol 1,3,4-trisphosphate 5/6-kinase;
• inositol 1,4,5 trisphosphate receptor type 1 (ITPR1);
• inositol 1,4,5-trisphosphate 3-kinase B (ITPKB);
• inositol monophosphatase;
• inositol polyphosphate-5-phosphatase, 145 kD (INPP5D);
• Ins (1,3,4,5) P4-binding protein;
• insulin (INS);
• insulin-like growth factor 2 receptor (IGF2R);
• integral membrane protein 1 (ITM1);
• integral membrane protein 2C (ITM2C);
• integral membrane protein Tmp21-I (p23);
• integrin beta 4 binding protein (ITGB4BP);
• integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41B) (ITGA2B);
• integrin, alpha 5 (fibronectin receptor, alpha polypeptide) (ITGA5);
• integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1;
• alpha polypeptide) (ITGAL);
• integrin, alpha M (complement componentreceptor 3, alpha;
• also known as CD11b (p170), macrophage antigen alpha polypeptide) (ITGAM);
• integrin, alpha X (antigen CD11C (p150), alpha polypeptide) (ITGAX);
• integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2 MSK12) (ITGB1);
• integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1;
• macrophage antigen 1 (mac-1) beta subunit) (ITGB2);
• integrin, beta 7 (ITGB7);
• Integrin-linked kinase (ILK);
• intercellular adhesion molecule 1 (CD54), human rhinovirus receptor (ICAM1);
• intercellular adhesion molecule 2 (ICAM2);
• intercellular adhesion molecule 3 (ICAM3);
• intercellular adhesion molecule 4, Landsteiner-Wiener blood group (ICAM4);
• Interferon consensus sequence binding protein 1 (ICSBP1);
• interferon regulatory factor 2 (IRF2);
• interferon regulatory factor 1 (IRF1);
• interferon regulatory factor 5 (IRF5);
• interferon, gamma-inducible protein 16 (IFI16);
• interferon, gamma-inducible protein 30 (IF130);
• interferon-induced protein 17 (IF117);
• interferon-induced protein 54 (IF154);
• interferon-inducible (1-8D);
• interferon-inducible (1-8 U);
• interferon-related developmental regulator 1 (IFRD1);
• interferon-stimulated transcription factor 3, gamma (48 kD) (ISGF3G);
• interleukin 1 receptor, type II (IL1R2);
• Interleukin 10 receptor, beta (I.10RB);
• interleukin 12 receptor, beta 1 (IL12RB1);
• interleukin 13 receptor, alpha 1 (IL13RA 1);
• interleukin 16 (lymphocyte chemoattractant factor) (IL16);
• interleukin 18 receptor 1 (IL18R1);
• interleukin 2 receptor, beta (IL2RB);
• interleukin 2 receptor, gamma (severe combined immunodeficiency) (IL2RG);
• interleukin 4 receptor (IL4R);
• interleukin 6 receptor (IL6R);
• interleukin 6 signal transducer (gp130, oncostatin M receptor) (IL6ST);
• interleukin 7 receptor (IL7R);
• interleukin 8 (IL8);
• interleukin 8 receptor alpha (IL8RA);
• interleukin 8 receptor, beta (IL8RB);
• interleukin enhancer binding factor 2, 45 kD (ILF2);
• interleukin enhancer binding factor 3, 90 kD (ILF3);
• interleukin-1 receptor-associated kinase 1 (IRAK1);
• interleukin-10 receptor, alpha (IL10RA);
• interleukin-11 receptor, alpha (IL11RA);
• intestinal carboxylesterase;
• IQ motif containing GTPase activating protein 1 (IQGAP1);
• IQ motif containing GTPase activating protein 2 (IQGAP2);
• isocitrate dehydrogenase 1 (NADP+), soluble (IDH1);
• isocitrate dehydrogenase 2 (NADP+), mitochondrial (IDH2);
• isocitrate dehydrogenase 3 (NAD+) alpha (IDH3A);
• isocitrate dehydrogenase 3 (NAD+) gamma (IDH3G);
• isolate TzCCR5-179 CCR5 receptor (CCR5);
• isopentenyl-diphosphate delta isomerase (IDJ1);
• Janus kinase 1 (a protein tyrosine kinase) (JAK1);
• Janus kinase 2 (a protein tyrosine kinase) (JAK2);
• Jk-recombination signal binding protein (RBPJK);
• JM1 protein;
• jumonji (mouse) homolog (JMJ);
• jun D proto-oncogene (JUND);
• jun dimerization protein;
• junction plakoglobin (JUP);
• kangai 1 (suppression of tumorigenicity 6, prostate;
• CD82 antigen (R2 leukocyte antigen, antigen detected by monoclonal and antibody IA4)) (KAI1);
• karyopherin (importin) beta 1 (KPNB1);
• karyopherin (importin) beta 2 (KPNB2);
• karyopherin alpha 1 (importin alpha 5) (KPNA1);
• karyopherin alpha 2 (RAG cohort 1, importin alpha 1) (DPNA2);
• karyopherin alpha 3 (importin alpha 4) (KPNA3);
• karyopherin alpha 4 (KPNA4);
• Katanin (80 kDa) (KAT);
• KE03 protein;
• Keratin 8 (KRT8);
• ketohexokinase (fructokinase) (KHK);
• KIAA0002 (KIAA0002);
• KIAA0005 (KIAA0005);
• KIAA0010 (KIAA0010);
• KIAA0016 (KIAA0016);
• KIAA0017 (KIAA0017);
• KIAA0022 (KIAA0022);
• KIAA0023 (KIAA0023);
• KIAA0024 (KIAA0024);
• KIAA0025 (KIAA0025);
• KIAA0026 (KIAA0026);
• KIAA0027;
• KIAA0032 (KIAA0032);
• KIAA0040 (KIAA0040);
• KIAA0050 (KIAA0050);
• KIAA0053 (KIAA0053);
• KIAA0057 (KIAA0057);
• KIAA0058 (KIAA0058);
• KIAA0063 (KIAA0063);
• KIAA0064 (KIAA0064);
• KIAA0066;
• KIAA0068;
• KIAA0073;
• KIAA0081;
• KIAA0084;
• KIAA0085;
• KIAA0088;
• KIAA0090;
• KIAA0092 (KIAA0092);
• KIAA0094;
• KIAA0095 (KIAA0095);
• KIAA0096;
• KIAA0097 (KIAA0097);
• KIAA0099 (KIAA0099);
• KIAA0102 (KIAA0102);
• KIAA0105;
• KIAA0121 (KIAA0121);
• KIAA0123;
• KIAA0128;
• KIAA0129 (KIAA0129);
• KIAA0130 (KIAA0130);
• KIAA0136;
• KIAA0137 (KIAA0137);
• KIAA0140 (KIAA0140);
• KIAA0141 (KIAA0141);
• KIAA0144 (KIAA0144);
• KIAA0146;
• KIAA0148 (KIAA0148);
• KIAA0154;
• KIAA0156;
• KIAA0160;
• KIAA0161 (KIAA0161);
• KIAA0164 (KIAA0164);
• KIAA0167 (KIAA0167);
• KIAA0168 (KIAA0168);
• KIAA0169;
• KIAA0171 (KIAA0171);
• KIAA0174 (KIAA0174);
• KIAA0179;
• KIAA0181;
• KIAA0183;
• KIAA0184;
• KIAA0193 (KIAA0193);
• KIAA0200 (KIAA0200);
• KIAA0210 (KIAA0210);
• KIAA0217;
• KIAA0219;
• KIAA0222 (KIAA0222);
• KIAA0223;
• KIAA0229;
• KIAA0232 (KIAA0232);
• KIAA0233 (KIAA0233);
• KIAA0235;
• KIAA0239;
• KIAA0240;
• KIAA0242;
• KIAA0248;
• KIAA0249 (KIAA0249);
• KIAA0253;
• KIAA0254 (KIAA0254);
• KIAA0255 (KIAA0255);
• KIAA0262 (KIAA0262);
• KIAA0263 (KIAA0263);
• KIAA0264;
• KIAA0268;
• KIAA0275 (KIAA0275);
• KIAA0304 (KIAA0304);
• KIAA0308;
• KIAA0310 (KIAA0310);
• KIAA0315 (KIAA0315);
• KIAA0329 (KIAA0329);
• KIAA0330;
• KIAA0332;
• KIAA0333;
• KIAA0336 (KIAA0336);
• KIAA0342 (KIAA0342);
• KIAA0344 (KIAA0344);
• KIAA0354 (KIAA0354);
• KIAA0365 (KIAA0365);
• KIAA0370;
• KIAA0372 (KIAA0372);
• KIAA0373 (KIAA0373);
• KIAA0375 (KIAA0375);
• KIAA0377 (KIAA0377);
• KIAA0379;
• KIAA0380 (KIAA0380);
• KIAA0382 (KIAA0382);
• KIAA0383;
• KIAA0386 (KIAA0386);
• KIAA0392;
• KIAA0397 (KIAA0397);
• KIAA0403;
• KIAA0404;
• KIAA0409;
• KIAA0421;
• KIAA0428 (KIAA0428);
• KIAA0429 (KIAA0429);
• KIAA0430 (KIAA0430);
• KIAA0432 (KIAA0432);
• KIAA0435 (KIAA0435);
• KIAA0438 (KIAA0438);
• KIAA0447 (KIAA0447);
• KIAA0449;
• KIAA0456;
• KIAA0458 (KIAA0458);
• KIAA0462;
• KIAA0465;
• KIAA0476 (KIAA0476);
• KIAA0489;
• KIAA0494 (KIAA0494);
• KIAA0515;
• KIAA0521;
• KIAA0525;
• KIAA0530;
• KIAA0532;
• KIAA0537 (KIAA0537);
• KIAA0540;
• KIAA0543;
• KIAA0544;
• KIAA0549;
• KIAA0551;
• KIAA0554;
• KIAA0561;
• KIAA0562 (KIAA0562);
• KIAA0563 (KIAA0563);
• KIAA0569 (KIAA0569);
• KIAA0571 (KIAA0571);
• KIAA0573;
• KIAA0576;
• KIAA0580;
• KIAA0584;
• KIAA0592;
• KIAA0596;
• KIAA0598 (KIAA0598);
• KIAA0608;
• KIAA0614;
• KIAA0615 (KIAA0615);
• KIAA0621;
• KIAA0648;
• KIAA0652 (KIAA0652);
• KIAA0668;
• KIAA0669;
• KIAA0671 (KIAA0671);
• KIAA0675 (KIAA0675);
• KIAA0676;
• KIAA0677 (KIAA0677);
• KIAA0678;
• KIAA0679;
• KIAA0680 (KIAA0680);
• KIAA0692;
• KIAA0697;
• KIAA0699;
• KIAA0700;
• KIAA0737 (KIAA0737);
• KIAA0748 (KIAA0748);
• KIAA0763 (KIAA0763);
• KIAA0769 (KIAA0769);
• KIAA0782;
• KIAA0796;
• KIAA0798 (KIAA0798);
• KIAA0823;
• KIAA0854;
• KIAA0856;
• KIAA0860;
• KIAA0862;
• KIAA0873;
• KIAA0892;
• KIAA0906;
• KIAA0991;
• killer cell lectin-like receptor subfamily B, member 1 (KLRB1);
• killer cell lectin-like receptor subfamily C, member 4 (KLRC4);
• kinectin 1 (kinesin receptor) (KTN1);
• kinesin family member 5B (KIF5 B);
• kinesin-like DNA binding protein;
• Kruppel related gene (clone pHKR1RS);
• Kruppel-like zinc finger protein Zf9;
• kruppel-type zinc finger protein, ZK1;
• L apoferritin;
• lactate dehydrogenase A (LDHA);
• lactate dehydrogenase B (LDHB);
• lactotransferrin (LTF);
• laminin receptor 1 (67 kD);
• Ribosomal protein SA (LAMR1);
• laminin receptor homolog {3′ region};
• laminin, gamma 1 (formerly LAMB2) (LAMC1);
• latent transforming growth factor beta binding protein 1 (LTBP1);
• LDLC;
• lectin, galactoside-binding, soluble, 2 (galectin 2) (LGALS2);
• lectin, galactoside-binding, soluble, 3 binding protein (galectin 6 binding protein) (LGALS3BP);
• leucine rich repeat (in FLIT) interacting protein 1 (LRRFIP1);
• leucocyte immunoglobulin-like receptor-5 (LIR-5);
• leucocyte immunoglobulin-like receptor-6a (LIR-6);
• leucocyte immunoglobulin-like receptor-7 (LIR-7);
• leukemia virus receptor 1 (GLVR1);
• leukocyte adhesion protein p150,95 alpha subunit;
• leukocyte antigen, HLA-A2;
• leukocyte immunoglobulin-like receptor (MIR-10);
• leukocyte tyrosine kinase (LTK);
• leukocyte-associated Ig-like receptor 1 (LIAR1);
• leukotriene A4 hydrolase (LTA4H);
• leupaxin (LDPL);
• ligase I, DNA, ATP-dependent (LIG1);
• LIM and SH3 protein 1 (LASP1);
• LIM domain kinase 2 (LIMK2);
• Line-1 repeat mRNA with 2 open reading frames;
• Line-1 repeat with 2 open reading frames;
• lipase A, lysosomal acid, cholesterol esterase (Wolman disease) (LIPA);
• lipase, hormone-sensitive (LIPE);
• LMP7;
• Lon protease-like protein (LONP);
• low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor) (LRP1);
• low density lipoprotein-related protein-associated protein 1 (alpha-2-macroglobulin receptor-associated protein 1) (LRPAP1);
• low-affinity Fc-gamma receptor IIA;
• LPS-induced TNF-alpha factor (PIG7);
• Lst-1;
• L-type amino acid transporter subunit LAT1;
• lung resistance-related protein (LRP);
• Lymphocyte antigen 75 (LY75);
• lymphocyte antigen 9 (LY9);
• lymphocyte antigen HLA-B*4402 and HLA-B*5101;
• lymphocyte cytosolic protein 1 (L-plastin) (LCP1);
• lymphocyte cytosolic protein 2 (SH2 domain-containing leukocyte protein of 76 kD) (LCP2);
• lymphocyte glycoprotein T1/Leu-1;
• lymphocyte-specific protein 1 (LSP1);
• lymphocyte-specific protein tyrosine kinase (LCK);
• lymphoid phosphatase LyP1;
• lymphoid-restricted membrane protein (LRMP);
• lymphoid-specific SP100 homolog (LYSP100-A);
• lymphoma proprotein convertase (LPC);
• lysosomal-associated membrane protein 1 (LAMP1);
• Lysosomal-associated membrane protein 2 (LAMP2);
• lysozyme (renal amyloidosis) (LYZ);
• lysyl-tRNA synthetase (KARS);
• M phase phosphoprotein 10 (U3 small nucleolar ribonucleoprotein) (MPP-10);
• M1-type and M2-type pyruvate kinase;
• m6A methyltransferase (MT-A70);
• mab-21 (C. elegans)-like 1 (MAB21L1);
• MacMarcks;
• macrophage-associated antigen (MM130);
• MADS box transcription enhancer factor 2, polypeptide A (myocyte enhancer factor 2A) (MEF2A);
• MADS box transcription enhancer factor 2, polypeptide C (myocyte enhancer factor 2C) (MEF2C);
• major histocompatibility complex class I beta chain (HLA-B);
• major histocompatibility complex, class I, A (HLA-A);
• major histocompatibility complex, class I, C (HAL-C);
• major histocompatibility complex, class I, E (HLA-E);
• major histocompatibility complex, class II, DM BETA (HLA-DMB);
• major histocompatibility complex, class II, DR beta 1 (HLA-DPB1);
• major histocompatibility complex, class II, DR beta 1 (HLA-DRB1);
• Major histocompatibility complex, class II, Y box-binding protein I;
• DNA-binding protein B (YB1);
• malate dehydrogenase 1, NAD (soluble) (mdh1);
• malate dehydrogenase 1, NAD (soluble) (MDH1);
• malonyl-CoA decarboxylase precursor;
• maltase-glucoamylase (mg);
• manic fringe (Drosophila) homolog (MFNG);
• mannose phosphate isomerase (MPI);
• mannose phosphate isomerase (mpi);
• mannose-6-phosphate receptor (cation dependent) (M6PR);
• mannose-P-dolichol utilization defect 1 (MPDU1);
• mannosidase, alpha B, lysosomal (MANB);
• mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase (MGAT1);
• map 4q35 repeat region;
• MAP kinase-interacting serine/threonine kinase 1 (MKNK1);
• MAP/ERK kinase 3 (MEKK3);
• MAP/ERK kinase 5 (MEKK5);
• MAP/microtubule affinity-regulating kinase 3 (MARK3);
• Marenostrin protein;
• MASL1;
• MAX dimerization protein (MAD);
• MaxiK potassium channel beta subunit;
• MBP-2 for MHC binding protein 2;
• Meis (mouse) homolog 3 (MEIS3);
• melanoma-associated antigen p97 (melanotransferrin);
• membrane cofactor protein (CD46, trophoblast-lymphocyte cross-reactive antigen) (MCP);
• membrane component, chromosome 17, surface marker 2 (ovarian carcinoma antigen CA125) (M17S2);
• membrane metallo-endopeptidase (neutral endopeptidase, enkephalinase, CALLA, CD10) (MME);
• membrane protein, palmitoylated 1 (55 kD) (MPP1);
• meningioma expressed antigen (MGEA);
• meningioma-expressed antigen 11 (MEA11);
• Menkes Disease (ATP7A) putative Cu++-transporting P-type ATPase;
• metallothionein 2A (MT2A);
• metaxin 1 (MTX1);
• methionine adenosyltransferase II, alpha (MAT2A);
• methylene tetrahydrofolate dehydrogenase (NAD+ dependent), methenyltetrahydrofolate cyclohydrolase (MTHFD2);
• methylenetetrahydrofolate dehydrogenase (NADP+ dependent), methenyltetrahydrofolate cyclohydrolase, formyltetrahydrofolate synthetase (MTHFD1);
• methyltransferase, putative;
• MHC class 1 region;
• MHC class I antigen (HLA-A2);
• MHC class I antigen (HLA-A33);
• MHC class I antigen (HLA-C);
• MHC class I antigen B*5801 (HLA-B);
• MHC class I antigen HLA-A (HLA-A);
• MHC class I antigen HLA-A (HLA-A-2402 allele);
• MHC class I antigen HLA-A11K;
• MHC class I antigen HLA-B (B*48 allele);
• MHC class I antigen HLA-B (HLA-B*1502 allele);
• MHC class I antigen HLA-B (HLA-B*40MD);
• MHC class I antigen HLA-B (HLA-B*4103 allele);
• MHC class I antigen HLA-B gene (HLA-B*4402 variant allele);
• MHC class I antigen HLA-B GN00110B*3910;
• MHC class I antigen HLA-Cw*04011;
• MHC class I antigen R69772HLA-A (A*0302);
• MHC class I antigen SHCHA (HLA-B*4403 variant);
• MHC class I histocompatibility antigen (HLA-B) (clone C21/14);
• MHC class I HLA B71;
• MHC class I HLA-A (Aw33.1);
• MHC class I HLA-B;
• MHC class I HLA-B (HLA-B-08NR allele);
• MHC class I HLA-B*3512;
• MHC class I HLA-B44.2 chain;
• MHC class I HLA-B51-cd3.3;
• MHC class I HLA-C allele;
• MHC class I HLA-Cw*0803;
• MHC class I HLA-Cw6;
• MHC class I lymphocyte antigen A2 (A2.1) variant DK1;
• MHC class I mic-B antigen;
• MHC class I polypeptide-related sequence A (MICA);
• MHC class II DNA Sequence (clone A37G7-1C11);
• MHC class II DQ-alpha associated with DRw6, DQw1 protein;
• MHC class II DQ-beta associated with DR2, DQw1 protein;
• MHC class II HAL-DQ-LTR5 (DQ,w8) DNA fragment, long terminal repeat region;
• MHC class II HLA-DRB1;
• MHC class II HLA-DRw11-beta-I chain (DRw11.3);
• MHC class II lymphocyte antigen (DPw4-beta-1);
• microsomal stress 70 protein ATPase core (stch);
• microtubule-associated protein 4 (MAP4);
• microtubule-associated protein 7 (MAP7);
• mineralocorticoid receptor (aldosterone receptor) (MLR);
• minichromosome maintenance deficient (S. cerevisiae) 3 (MCM31);
• minichromosome maintenance deficient (S. cerevisiae) 3-associated protein (MCM3AP);
• minichromosome maintenance deficient (S. cerevisiae) 5 (cell division cycle 46) (MCM5);
• mitochondrial 16S rRNA;
• mitochondrial ATP synthase (F1-ATPase) alpha subunit;
• mitochondrial ATP synthase c subunit (P1 form);
• mitochondrial cytochrome b small subunit of complex II;
• mitochondrial DNA loop attachment sequences (clone LAS34);
• mitochondrial DNA polymerase accessory subunit precursor (MtPolB) nuclear gene encoding mitochondrial protein;
• mitochondrial DNA, complete genome;
• mitochondrial inner membrane preprotein translocase Tim17a;
• mitochondrial loop attachment sequence (clone LAS88);
• mitochondrial NADH dehydrogenase subunit 2 (ND2);
• mitochondrial translational initiation factor 2 (MTIF2);
• mitochondrion cytochrome b;
• mitogen inducible gene mig-2;
• mitogen-activated protein kinase-activated protein kinase 3 (MAPKAPK3);
• MLN51;
• moesin (MSN);
• monocytic leukaemia zinc finger protein (MOZ);
• MOP1 ( );
• motor protein (Hs.78504);
• mouse double minute 2, human homolog of;
• p53-binding protein (MDM2);
• M-phase phosphoprotein 6 (MPP-6);
• M-phase phosphoprotein, mpp11;
• MPS1;
• Mr 110,000 antigen;
• mu-adaptin-related protein-2;
• mu subunit of AP-4 (MU-ARP2);
• murine leukemia viral (bmi-1) oncogene homolog (BMI1);
• mutant (Daudi) beta2-microglobulin;
• mutated in colorectal cancers (MCC);
• myeloid cell leukemia sequence 1 (BCL2-related) (MCL1);
• myeloid cell nuclear differentiation antigeN (MNDA);
• myeloid differentiation primary response gene (88) (MYD88);
• myeloid leukemia factor 2 (MLF2);
• myeloid/lymphoid or mixed-lineage leukemia (trithorax (Drosophila) homolog);
• translocated to, 7 (MLLT7);
• MYH9 (cellular myosin heavy chain);
• myomesin (M-protein) 2 (165 kD) (MYOM2);
• myosin IE (MYO1E);
• myosin light chain kinase (MLCK);
• myosin phosphatase, target subunit 1 (MYPT1);
• myosin, heavy polypeptide 9, non-muscle (MYH9);
• myosin, light polypeptide, regulatory, non-sarcomeric (20 kD) (MLCB);
• myosin-I beta;
• myristoylated alanine-rich protein kinase C substrate (MARCKS, 80K-L) (MACS);
• myxovirus (influenza) resistance 1, homolog of murine (interferon-inducible protein p78) (MX1);
• myxovirus (influenza) resistance 2, homolog of murine (MX2);
• N-acetylgalactosaminidase, alpha-(NAGA);
• N-acetylglucosamine receptor 1 (thyroid) (NAGR1);
• NACP/alpha-synuclein;
• N-acylaminoacyl-peptide hydrolase (APEH);
• N-acylsphingosine amidohydrolase (acid ceramidase) (ASAH);
• NAD+-specific isocitrate dehydrogenase beta subunit precursor (encoding mitochondrial protein);
• NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 5 (13 kD, B13) (NDUFA5);
• NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5 (16 kD, SGDH) (NDUFB5);
• NADH dehydrogenase (ubiquinone) Fe—S protein 2 (49 kD) (NADH-coenzyme Q eductase) (NDUFS2);
• NADH dehydrogenase (ubiquinone) flavoprotein 2 (24 kD) (NDUFV2);
• NADH:ubiquinone dehydrogenase 51 kDa subunit (NDUFV1);
• Nardilysin (N-arginine dibasic convertase) (NRD1);
• nascent-polypeptide-associated complex alpha polypeptide (NACA);
• natural killer cell group 7 sequence (NKG7);
• natural killer cell transcript 4 (NK4);
• natural killer-associated transcript 3 (NKAT3);
• natural killer-associated transcript 5 (NKAT5);
• natural killer-tumor recognition sequence (NKTR);
• N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 2 (NDST2);
• Ndr protein kinase;
• Nedd-4-like ubiquitin-protein ligase WWP1;
• nel (chicken)-like 2 (NELL2);
• N-ethylmaleimide-sensitive factor attachment protein, alpha (NAPA);
• N-ethylmaleimide-sensitive factor attachment protein, gamma (NAPG);
• neural precursor cell expressed, developmentally down-regulated 5 (NEDD5);
• neural precursor cell expressed, developmentally down-regulated 8 (NEDD8);
• neuregulin 1 (NRG1);
• neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS);
• Neurofibromin 2 (bilateral acoustic neuroma) (NF2);
• neuronal apoptosis inhibitory protein (NAIP);
• neuronal cell adhesion molecule (NRCAM);
• neuropathy target esterase (NTE);
• neurotrophic tyrosine kinase, receptor, type 1 (NTRK1);
• neutrophil cytosolic factor 4 (40 kD);
• NG31;
• nibrin (NBS);
• NIK;
• Ninjurin 1;
• nerve injury-induced protein-1;
• Nmi;
• N-myristoyltransferase 1 (NMT1);
• No arches-like (zebrafish) zinc finger protein (NAR);
• non-histone chromosome protein 2 (S. cerevisiae)-like 1 (NHP2L1);
• non-muscle alpha-actinin;
• non-muscle myosin alkali light chain (Hs.77385);
• non-neuronal enolase (EC 4.2.1.11);
• non-receptor tyrosine phosphatase 1;
• normal keratinocyte substraction library mRNA, clone H22a;
• notch group protein (N);
• novel protein;
• novel T-cell activation protein;
• N-sulfoglucosamine sulfohydrolase (sulfamidase) (SGSH);
• insulin induced gene 1 (INSIG1);
• integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) (ITGA14);
• interferon, gamma-inducible protein 16 (IFI16);
• interleukin 1, beta (IL1RB);
• nuclear antigen H731-like protein;
• nuclear antigen Sp100 (SP100);
• nuclear autoantigenic sperm protein (histone-binding) (NASP);
• Nuclear domain 10 protein (NDP52);
• Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2);
• Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105) (NFKB1);
• nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (NFKBIA);
• nuclear factor related to kappa B binding protein (NFRKB);
• nuclear mitotic apparatus protein 1 (NUMA1);
• nuclear receptor coactivator 2 (GRIP1);
• nuclear receptor coactivator 3 (AIB3);
• nuclear receptor coactivator 4 (ELE1);
• nuclear receptor interacting protein 1 (NRIP1);
• nuclear respiratory factor 1 (NRF1);
• nuclear RNA helicase, DECD variant of DEAD box family (DDXL);
• nuclear transcription factor Y, alpha (NFYA);
• nuclear transcription factor, X-box binding 1 (NFX1);
• nuclear transport factor 2 (placental protein 15) (PP15);
• nucleobindin 1 (NUCB1);
• nucleolar phosphoprotein p130 (P130);
• nucleolar protein (KKE/D repeat) (NOP56);
• nucleolar protein (MSP58);
• nucleolar protein 1 (120 kD) (NOL1);
• nucleolar protein p40;
• nucleolin (NCL);
• nucleophosmin (nucleolar phosphoprotein B23, numatrin) (NPM1);
• nucleophosmin-retinoic acid receptor alpha fusion protein NPM-RAR long form;
• nucleoporin 153 kD (NUP153);
• nucleoporin 98 kD (NUP98);
• nucleosome assembly protein;
• nucleosome assembly protein 1-like 1 (NAP1L1);
• nucleosome assembly protein 1-like 4 (NAP1L4);
• nucleosome assembly protein, 5′UTR;
• olfactory receptor (OR7-141);
• oligodendrocyte myelin glycoprotein (OMG);
• O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-acetylglucosamine:polypeptide-N-acetylglucosaminyl transferase) (OGT);
• ORF (Hs.77868);
• ORF1;
• MER37;
• origin recognition complex, subunit 2 (yeast homolog)-like (ORC2L);
• ornithine aminotransferase (gyrate atrophy) (OAT);
• ornithine decarboxylase (ODC);
• ornithine decarboxylase antizyme, ORF 1 and ORF 2;
• orphan receptor (Hs.100221);
• OS-9 precursor;
• ovel centrosomal protein RanBPM (RANBPM);
• over-expressed breast tumor protein;
• oviductal glycoprotein 1, 120 kD (OVGP1);
• oxidase (cytochrome c) assembly 1-like (OXA1L);
• oxoglutarate dehydrogenase (lipoamide) (OGDH);
• oxysterol binding protein (OSBP);
• OZF;
• p21/Cdc42/Rac1-activated kinase 1 (yeast Ste20-related) (PAK1);
• p40;
• P47 LBC oncogene;
• p53-induced protein (PIG11);
• p62 nucleoporin;
• p63 mRNA for transmembrane protein;
• palmitoyl-protein thioesterase (ceroid-lipofuscinosis, neuronal 1, infantile;
• Haltia-Santavuori disease) (PPT);
• papillary renal cell carcinoma (translocation-associated) (PRCC);
• PAR protein;
• PAX3/forkhead transcription factor gene fusion;
• paxillin (PXN);
• PBK1 protein;
• PDZ domain protein (Drosophila inaD-like) (INALD);
• peptidase D (PEPD);
• peptidylprolyl isomerase A (cyclophilin A) (PPIA);
• peptidylprolyl isomerase D (cyclophilin D) (PPID);
• peptidylprolyl isomerase E (cyclophilin E) (PPIE);
• perform 1 (preforming protein) (PRF1);
• peroxisomal acyl-CoA thioesterase (PTE1);
• Peroxisomal acyl-coenzyme A oxidase;
• peroxisomal farnesylated protein (PXF);
• phorbol-12-myristate-13-acetate-induced protein (PMAIP1);
• Phosphate carrier, mitochondrial (PHC);
• phosphate cytidylyltransferase 1, choline, alpha isoform (PCYT1A);
• phosphatidylinositol 3-kinase delta catalytic subunit;
• phosphatidylinositol 4-kinase, catalytic, beta polypeptide (PIK4CB);
• phosphatidylinositol glycan, class H (PIGH);
• phosphatidylinositol transfer protein (PI-TPbeta);
• phosphatidylinositol transfer protein, membrane-associated (PITPNM);
• phosphatidylinositol-4-phosphate 5-kinase, type II, alpha (PIP5K2A);
• phosphatidylinositol-4-phosphate 5-kinase, type II, beta (PIP5K2B);
• phosphodiesterase 7A (PDE7A);
• phosphodiesterase IB (PDES1B);
• phosphoglucomutase 1 (PGM1);
• phosphogluconate dehydrogenase (PGD);
• phosphoglycerate kinase 1 (PGK1);
• phosphoglycerate mutase 1 (brain) (PGAM1);
• phosphoglycerate mutase 2 (muscle) (PGAM2);
• phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA);
• phosphoinositide-3-kinase, catalytic, delta polypeptide (PIK3CD);
• phosphoinositide-3-kinase, catalytic, gamma polypeptide (PIK3CG);
• phospholipase C;
• phospholipase C, delta 1 (PLCD1);
• phospholipase C, gamma 1 (formerly subtype 148) (PLCG1);
• phospholipid scramblase;
• phosphoribosyl pyrophosphate synthetase-associated protein 1 (PRPSAP1);
• phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase (GART);
• phosphorylase kinase, alpha 2 (liver), glycogen storage disease IX (PHKA2);
• phosphorylase, glycogen;
• brain (PYGB);
• phosphorylase, glycogen;
• liver (Hers disease, lycogen storage disease type VI) (PYGL);
• phosphorylation regulatory protein HP-10;
• phosphotidylinositol transfer protein (PITPN);
• pigment epithelium-derived factor (PEDF);
• pim-1 oncogene (PIM1);
• pinin, desmosome associated protein (PNN);
• placenta (Diff33);
• placenta (Diff48);
• plasminogen activator, urokinase receptor (PLAUR);
• platelet factor 4 (PF4);
• platelet/endothelial cell adhesion molecule (CD31 antigen) (PECAM1);
• platelet-activating factor acetylhydrolase 2 (40 kD) (PAFAH2);
• platelet-activating factor acetylhydrolase, isoform Ib, alpha subunit (45 kD) (PAFAH1B1);
• platelet-activating factor receptor (PTAFR);
• pleckstrin (PLEK);
• pleckstrin homology, Sec7 and coiled/coil domains 1 (cytohesin 1) (PSCD1);
• pleckstrin homology, Sec7 and coiled/coil domains, binding protein (PSCDBP);
• pM5 protein;
• PMP69;
• poly(A) polymerase (PAP);
• poly(A)-binding protein-like 1 (PABPL1);
• poly(rC)-binding protein 1 (PCBP1);
• polyadenylate binding protein;
• polycystic kidney disease 1 (autosomal dominant) (PKD1);
• polymerase (DNA directed), beta (POLB);
• polymerase (DNA directed), gamma (POLG);
• polymerase (RNA) II (DNA directed) polypeptide A (220 kD) (POLR2A);
• polymyositis/scleroderma autoantigen 2 (100 kD) (PMSCL2);
• polypyrimidine tract binding protein (heterogeneous nuclear ribonucleoprotein I) (PTB);
• positive regulator of programmed cell death ICH-1L (Ich-1);
• postmeiotic segregation increased 2-like 12 (PMS2L12);
• postmeiotic segregation increased 2-like 8 (PMS2L8);
• potassium inwardly-rectifying channel, subfamily J, member 15 (KCNJ15);
• potassium voltage-gated channel, KQT-like subfamily, member 1 (KCNQ1);
• POU domain, class 2, associating factor 1 (POU2AF1);
• POU domain, class 2, transcription factor 1 (POU2F1);
• PPAR binding protein (PPARBP);
• PPAR gamma2;
• pre-B-cell colony-enhancing factor (PBEF);
• prefoldin 1 (PFDN1);
• prefoldin 5 (PRFLD5);
• pregnancy-associated plasma protein A (PAPPA);
• pre-mRNA splicing factor SRp20, 5′UTR;
• preprotein translocase (TIM17);
• prion protein;
• prion protein (p27-30) (Creutzfeld-Jakob disease, Gerstmann-Strausler-Scheinker syndrome, fatal familial insomnia) (PRNP);
• procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase, Ehlers-Danlos syndrome type VI) (PLOD);
• procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide 1 (P4HA1);
• procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), beta polypeptide (protein disulfide isomerase;
• thyroid hormone binding protein p55) (P4HB);
• profilin 1 (PFN1);
• progesterone receptor-associated p48 protein (P48);
• prohibitin (PHB);
• proliferating cell nuclear antigen (PCNA);
• proliferation-associated gene A (natural killer-enhancing factor A) (PAGA);
• proline-serine-threonine phosphatase interacting protein 1 (PSTPIP1);
• prolyl endopeptidase (PREP);
• prolylcarboxypeptidase (angiotensinase C) (PRCP);
• promyelocytic leukemia (PML);
• properdin P factor, complement (PFC);
• pro-platelet basic protein (includes platelet basic protein, beta-thromboglobulin, connective tissue-activating peptide III, neutrophil-activating peptide-2) (PPBP);
• proprotein convertase subtilisin/kexin type 7 (PCSK7);
• prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy) (PSAP);
• prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (PTGS1);
• prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (PTGS2);
• prostate carcinoma tumor antigen (pcta-1);
• protease inhibitor 1 (anti-elastase), alpha-1-antitrypsin (PI);
• protease inhibitor 2 (anti-elastase), proteasome (prosome, macropain) 26S subunit, ATPase, 1 (PSMC1);
• proteasome (prosome, macropain) 26S subunit, ATPase, 3 (PSMC3);
• proteasome (prosome, macropain) 26S subunit, ATPase, 4 (PSMC4);
• proteasome (prosome, macropain) 26S subunit, ATPase, 5 (PSMC5);
• proteasome (prosome, macropain) 26S subunit, ATPase, 6 (PMSC6);
• proteasome (prosome, macropain) 26S subunit, non-ATPase, 11 (PSMD11);
• proteasome (prosome, macropain) 26S subunit, non-ATPase, 2 (PSMD2);
• proteasome (prosome, macropain) 26S subunit, non-ATPase, 5 (PSMD5);
• proteasome (prosome, macropain) 26S subunit, non-ATPase, 7 (Mov34 homolog) (PMSD7);
• proteasome (prosome, macropain) 26S subunit, on-ATPase, 12 (PMSD12);
• proteasome (prosome, macropain) activator subunit 1 (PA28 alpha) (PSME1);
• proteasome (prosome, macropain) subunit, alpha type, 3 (PSMA3);
• proteasome (prosome, macropain) subunit, alpha type, 5 (PSMA5);
• proteasome (prosome, macropain) subunit, alpha type, 7 (PSMA7);
• proteasome (prosome, macropain) subunit, beta type, 1 (PSMB1);
• proteasome (prosome, macropain) subunit, beta type, 10 (PSMB10);
• proteasome (prosome, macropain) subunit, beta type, 6 (PMSB6);
• proteasome (prosome, macropain) subunit, beta type, 8 (large multifunctional protease 7) (PSMB8);
• proteasome (prosome, macropain) subunit, beta type, 9 (large multifunctional protease 2) (PSMB9);
• proteasome (prosome, macropain) subunit, beta ype, 7 (PSMB7);
• protective protein for beta-galactosidase (galactosialidosis) (PPGB);
• protein A alternatively spliced form 2 (A-2);
• protein activator of the interferon-induced protein kinase (PACT);
• protein disulfide isomerase-related protein (P5);
• protein geranylgeranyltransferase type I, beta subunit (PGGT1B);
• protein homologous to chicken B complex protein, guanine nucleotide binding (H12.3);
• protein kinase A anchoring protein;
• protein kinase C substrate 80K—H (PRKCSH);
• protein kinase C, beta 1 (PRKCB1);
• protein kinase C, delta (PRKCD);
• protein kinase C, eta (PRKCH);
• Protein kinase C-like 1 (PRKCL1);
• protein kinase, AMP-activated, gamma 1 non-catalytic subunit (PRKAG1);
• protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific extinguisher 1) (PRKAR1A);
• protein kinase, DNA-activated, catalytic polypeptide (PRKDC);
• protein kinase, mitogen-activated 1 (MAP kinase 1;
• p40, p41) (PRKM1);
• protein kinase, mitogen-activated 6 (extracellular signal-regulated kinase, p97) (PRKM6);
• protein kinase, mitogen-activated, kinase 3 (MAP kinase kinase 3) (PRKMK3);
• protein phosphatase 1, catalytic subunit, alpha isoform (PPP1CA);
• protein phosphatase 1, regulatory subunit 10 (PPPR10);
• protein phosphatase 1, regulatory subunit 7 (PPP1R7);
• protein phosphatase 2 (formerly 2A), catalytic subunit, beta isoform (PPP2CB);
• protein phosphatase 2 (formerly 2A), regulatory subunit B″ (PR 72), alpha isoform and (PR 130), beta isoform (PPP2R3);
• protein phosphatase 2, regulatory subunit B (B56), alpha isoform (PPP2R5A);
• protein phosphatase 2, regulatory subunit B (B56), delta isoform (PPP2R5D);
• protein phosphatase 2, regulatory subunit B (B56), gamma isoform (PPP2R5C);
• protein phosphatase 2A regulatory subunit alpha-isotype (alpha-PR65);
• protein phosphatase 4 (formerly X), catalytic subunit (PPP4C);
• protein tyrosine kinase 2 beta (PTK2B);
• protein tyrosine phosphatase epsilon;
• protein tyrosine phosphatase type IVA, member 2 (PTP4A2);
• protein tyrosine phosphatase, non-receptor type 1 (PTPN1);
• protein tyrosine phosphatase, non-receptor type 12 (PTPN12);
• protein tyrosine phosphatase, non-receptor type 2 (PTPN2);
• protein tyrosine phosphatase, non-receptor type 4 (megakaryocyte) (PTPN4);
• protein tyrosine phosphatase, non-receptor type 6 (PTPN6);
• protein tyrosine phosphatase, non-receptor type 7 (PTPN7);
• protein tyrosine phosphatase, receptor type, alpha polypeptide (PTPRA);
• protein tyrosine phosphatase, receptor type, c polypeptide (PTPRC);
• protein tyrosine phosphatase, receptor type, M (PTPRM);
• protein tyrosine phosphatase, receptor type, N polypeptide 2 (PTPRN2);
• protein with polyglutamine repeat (ERPROT213-21);
• protein-kinase, interferon-inducible double stranded RNA dependent inhibitor (PRKRI);
• protein-L-isoaspartate (D-aspartate) O-methyltransferase (PCMT1);
• proteoglycan 1, secretory granule (PRG1);
• prothymosin, alpha (gene sequence 28) (PTMA);
• prp28, U5 snRNP 100 kd protein (U5-100K);
• PRP4/STK/WD splicing factor (HPRP4P);
• PTK7 protein tyrosine kinase 7 (PTK7);
• purinergic receptor P2X, ligand-gated ion channel, 4 (P2RX4);
• purinergic receptor P2X, ligand-gated ion channel, 7 (P2RX7);
• puromycin-sensitive aminopeptidase (PSA);
• putative ATP (GTP)-binding protein;
• putative brain nuclearly-targeted protein (KIAA0765);
• putative chemokine receptor;
• GTP-binding protein (HM74);
• putative dienoyl-CoA isomerase (ECH1);
• putative G-binding protein;
• Putative human HLA class II associated protein I (PHAP1);
• Putative L-type neutral amino acid transporter (KIAA0436);
• putative mitochondrial space protein 32.1;
• putative nucleic acid binding protein;
• putative outer mitochondrial membrane 34 kDa translocase Htom34;
• putative translation initiation factor (SUI1);
• putative tumor suppressor protein (123F2);
• pyrroline 5-carboxylate reductase;
• pyruvate dehydrogenase (lipoamide) alpha 1 (PDHA1);
• pyruvate dehydrogenase (lipoamide) beta (PDHB);
• Pyruvate dehydrogenase complex, lipoyl-containing component X;
• E3-binding protein (PDX1);
• pyruvate kinase, muscle (PKM2);
• RAB, member of RAS oncogene family-like (RABL);
• RAB1, member RAS oncogene family (RAB1);
• RAB11A, member RAS oncogene family (RAB11A);
• RAB11B, member RAS oncogene family (Rab11B);
• RAB27A, member RAS oncogene family (RAB27A);
• RAB5B, member RAS oncogene family (RAB5B);
• RAB6, member RAS oncogene family (RAB6);
• RAB7, member RAS oncogene family (RAB7);
• RAB7, member RAS oncogene family-like 1 (RAB7L1);
• RAB9, member RAS oncogene family (RAB9);
• RAD50 (S. cerevisiae) homolog (RAD50);
• RAD51 (S. cerevisiae) homolog C (RAD51C);
• Radin blood group (RD);
• RAE1 (RNA export 1, S. pombe) homolog (RAE1);
• ralA-binding protein (RLIP76);
• RAN binding protein 2-like 1 (RANBP2L1);
• Ran GTPase activating protein 1 (RANGAP1);
• transforming growth factor, beta receptor II (70-80 kD) (TGFBR2);
• RAP1A, member of RAS oncogene family (RAP1A);
• RAR-related orphan receptor C (RORC);
• RAS guanyl releasing protein 2 (calcium and DAG-regulated);
• ras homolog gene family, member A (ARHA);
• ras homolog gene family, member G (rho G) (ARHG);
• ras homolog gene family, member H (ARHH);
• ras inhibitor (RIN1);
• Ras-GTPase activating protein SH3 domain-binding protein 2 (KIAA0660);
• Ras-GTPase-activating protein SH3-domain-binding protein (G3BP);
• ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2) (RAC2);
• RBQ-1;
• regulator of Fas-induced apoptosis (TOSO);
• regulator of G protein signalling 6 (RGS6);
• regulator of G-protein signalling 14 (RGS14);
• regulator of G-protein signalling 2, 24 kD (RGS2);
• regulatory factor X, 4 (influences HLA class II expression) (RFX4);
• regulatory factor X, 5 (influences HLA class II expression (RFX5);
• replication protein A1 (RPA1);
• reproduction 8 (D8S2298E);
• requiem, apoptosis response zinc finger gene (REQ);
• restin (Reed-Steinberg cell-expressed intermediate filament-associated protein) (RSN);
• retinoblastoma 1 (including osteosarcoma) (RB1);
• retinoblastoma binding protein 2 homolog 1 (RBBP2H1);
• retinoblastoma-binding protein 1 (RBBP1);
• retinoblastoma-binding protein 2 (RBBP2);
• retinoblastoma-binding protein 4 (RBBP4);
• retinoblastoma-binding protein 7 (RBBP7);
• retinoblastoma-like 2 (p130) (RBL2);
• retinoic acid receptor responder (tazarotene induced) 3 (RARRES3);
• retinoic acid receptor, alpha (RARA);
• retinoic acid responsive (NN8-4AG);
• retinoid X receptor beta (RXR-beta);
• REV3 (yeast homolog)-like, catalytic subunit of DNA polymerase zeta (REV3L);
• Rho GDP dissociation inhibitor (GDI) beta (ARHGDIB);
• Rho GTPase activating protein 4 (ARHGAP4);
• Rho-associated, coiled-coil containing protein kinase 2 (ROCK2);
• ribonuclease 6 precursor (RNASE6PL);
• ribonuclease, RNase A family, 2 (liver, eosinophil-derived neurotoxin) (RNASE2);
• ribonuclease/angiogenin inhibitor (RNH);
• ribonucleoside diphosphate reductase M1 subunit;
• ribophorin I (RPN1);
• ribophorin II (RPN2);
• ribosomal 18S rRNA;
• ribosomal 28S RNA;
• ribosomal protein L10 (RPL10);
• ribosomal protein L11 (RPL11);
• ribosomal protein L12 (RPL19);
• ribosomal protein L14 (RPL14);
• ribosomal protein L17 (RPL17);
• ribosomal protein L18 (RPL18);
• ribosomal protein L18a (RPL18A);
• ribosomal protein L18a homologue;
• ribosomal protein L19 (RPL19);
• ribosomal protein L21 (RPL21);
• ribosomal protein L22 (RPL22);
• ribosomal protein L23 (RPL23);
• ribosomal protein L23a (RPL23A);
• ribosomal protein L26 (RPL26);
• ribosomal protein L27 (RPL27);
• ribosomal protein L27a (RPL27A);
• ribosomal protein L28 (RPL28);
• ribosomal protein L29 (RPL29);
• ribosomal protein L3 (RPL3);
• ribosomal protein L3 homologue;
• ribosomal protein L30 (RPL30);
• ribosomal protein L31 (RPL31);
• ribosomal protein L32 (RPL32);
• ribosomal protein L33-like (RPL33L);
• ribosomal protein L34 (RPL34);
• ribosomal protein L37 (RPL37);
• ribosomal protein L37a;
• ribosomal protein L38 (PRL38);
• ribosomal protein L4 (RPL4);
• ribosomal protein L41 (RPL41);
• ribosomal protein L5 (RPL5);
• ribosomal protein L6 (RPL6);
• ribosomal protein L7 (RPL7);
• ribosomal protein L7a (RPL7A);
• ribosomal protein L8 (RPL8);
• ribosomal protein L9 (RPL9);
• ribosomal protein 510 (RPS10);
• ribosomal protein S11 (RPS11);
• ribosomal protein S12 (RPS12);
• ribosomal protein S13 (RPS13);
• ribosomal protein S14 (RPS14);
• ribosomal protein S15 (RPS15);
• ribosomal protein S16 (RPS16);
• ribosomal protein S17 (RPS17);
• ribosomal protein S18;
• ribosomal protein S19 (RPS19);
• ribosomal protein S2 (RPS2);
• ribosomal protein S20 (RPS20);
• ribosomal protein S21 (RPS21);
• ribosomal protein 523 (RPS23);
• ribosomal protein S24 (RPS24);
• ribosomal protein S25 (RPS25);
• ribosomal protein S26 (RPS26);
• ribosomal protein S27 ((metallopanstimulin 1) (RPS27);
• ribosomal protein S28 (RPS28);
• ribosomal protein S29 (RPS29);
• ribosomal protein S3 (RPS3);
• ribosomal protein S3A (RPS3A);
• ribosomal protein S4, X-linked (RPS4X);
• ribosomal protein S4, Y-linked (RPS4Y);
• ribosomal protein S5 (RPS5);
• ribosomal protein S6 (RPS6);
• ribosomal protein S6 kinase, 90 kD, polypeptide 1 (RPS6KA1);
• ribosomal protein S6 kinase, 90 kD, polypeptide 2 (RPS6KA2);
• ribosomal protein S7 (RPS7);
• ribosomal protein S8 (RPS8);
• ribosomal protein S9 (RPS9);
• ribosomal protein, large, P0 (RPLP0);
• ribosomal protein, large, P1 (RPLP1);
• ribosomal RNA 28S;
• ribosomal RNA, 165;
• ring finger protein 3 (RNF3);
• ring finger protein 4 (RNF4);
• ring zinc-finger protein (ZNF127-Xp);
• RNA (guanine-7-) methyltransferase (RNMT);
• RNA binding motif protein 5 (RBM5);
• RNA binding motif, single stranded interacting protein 2 (RBMS2);
• RNA helicase (putative), (Myc-regulated DEAD box protein) (MRD8);
• RNA helicase-related protein;
• RNA pol II largest subunit;
• RNA polymerase I subunit (RPA40);
• RTVP-1 protein;
• S100 calcium-binding protein A10 (annexin II ligand, calpactin I, light polypeptide (p11)) (S100A10);
• S100 calcium-binding protein A11 (calgizzarin) (S100A11);
• S100 calcium-binding protein A4 (calcium protein, calvasculin, metastasin, murine placental homolog) (S100A4);
• S100 calcium-binding protein A8 (calgranulin A) (S100A8);
• S100 calcium-binding protein A9 (calgranulin B) (S100A9);
• S164 gene;
• S-adenosylmethionine decarboxylase 1 (AMD1);
• SB classII histocompatibility antigen alpha-chain;
• SC35-interacting protein 1 (SRRP129);
• scaffold attachment factor B (SAFB);
• scRNA molecule, transcribed from Alu repeat;
• SEC14 (S. cerevisiae)-like (SEC14L);
• SEC23-like protein B (SEC23B);
• SEC63 (SEC63);
• secreted protein, acidic, cysteine-rich (osteonectin) (SPARC);
• secretory carrier membrane protein 1 (SCAMP1);
• secretory carrier membrane protein 2 (SCAMP2);
• secretory carrier membrane protein 3 (SCAMP3);
• secretory granule proteoglycan core (clones lambda-PG[6,7,8]);
• selectin L (lymphocyte adhesion molecule 1) (SELL);
• selectin P ligand (SELPLG);
• sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4D (SEMA4D);
• Ser/Arg-related nuclear matrix protein (plenty of prolines 101-like) (SRM160);
• seine palmitoyltransferase subunit I (SPTI);
• seine palmitoyltransferase, subunit II (LCB2);
• serine protease;
• seine protease inhibitor, Kunitz type, 2 (SPINT2);
• serine/threonine kinase 10 (STK10);
• serine/threonine kinase 19 (STK19);
• serine/threonine kinase 4 (STK4);
• serine/threonine protein kinase KKIALRE (KKIALRE);
• serine/threonine protein-kinase (NIK);
• serologically defined colon cancer antigen 16 (NY—CO-16);
• serologically defined colon cancer antigen 33 (SDCCAG33);
• serum/glucocorticoid regulated kinase (SGK);
• SET domain, bifurcated 1 (SETDB1);
• SH2 domain protein 1A, Duncan's disease lymphoproliferative syndrome) (SH2D1A);
• SH3 binding protein (SAB);
• SH3 domain protein 1B (SH3D1B);
• SH3-binding domain glutamic acid-rich protein like (SH3BGRL);
• SH3-domain GRB2-like 1 (SH3GL1);
• SHC (Src homology 2 domain-containing) transforming protein 1 (SHC1);
• siah binding protein 1 (SiahBP1);
• Sialomucin CD164 (CD164);
• sialophorin (gpL115, leukosialin, CD43) (SNP);
• sialyltransferase (STHM);
• sialyltransferase 1 (beta-galactoside alpha-2,6-sialytransferase) (SIAT1);
• sialyltransferase 4A (beta-galactosidase alpha-2,3-sialytransferase) (SIAT4A);
• sialyltransferase 8 (alpha-2,8-polysialytransferase) D (SIAT8D);
• signal peptidase 25 kDa subunit;
• signal recognition particle 14 kD (homologous Alu RNA-binding protein) (SRP14);
• signal recognition particle 54 kD (SRP54);
• signal recognition particle 9 kD (SRP9);
• signal recognition particle receptor (‘docking protein’) SRPR;
• signal regulatory protein, beta, 1 (SIRP-BETA-1);
• signal sequence receptor, alpha (translocon-associated protein alpha) (SSR1);
• signal sequence receptor, beta (translocon-associated protein beta) (SSR2);
• signal transducer and activator of transcription (STAT5A);
• signal transducer and activator of transcription 2, 113 KD (STAT2);
• signal transducer and activator of transcription 3 (acute-phase response factor) (STAT3);
• signal transducer and activator of transcription 5A (STAT5A);
• signal transducing adaptor molecule (SH3 domain and ITAM motif) 1 (STAM);
• silencing mediator of retinoid and thyroid hormone action (SMRT);
• SIT protein;
• Sjogren syndrome antigen A1 (52 kD, ribonucleoprotein autoantigen SS-A/Ro) (SSA1);
• SKAP55 homologue (SKAP-HOM);
• skb1 (S. pombe) homolog (SKB1);
• skeletal muscle abundant protein;
• SMA3 (SMA3);
• small acidic protein;
• small EDRK-rich factor 2 (SERF2);
• small inducible cytokine A5 (RANTES) (SCYA5);
• small inducible cytokine subfamily C, member 2 (SCYC2);
• small nuclear ribonucleoprotein polypeptide B″ (SNRPB2);
• small nuclear ribonucleoprotein polypeptide N(SNRPN);
• small nuclear ribonucleoprotein polypeptides B and B1 (SNRPB);
• small nuclear RNA activating complex, polypeptide 5, 19 kD (SNAPC5);
• smallest subunit of ubiquinol-cytochrome c reductase;
• SMC (mouse) homolog, X chromosome (SMCX);
• SMT3B protein (2);
• SNC19;
• SNC73 protein (SNC73);
• solute carrier family 1 (neutral amino acid transporter), member 5 (SLC1A5);
• Solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1 (SLC11A1);
• solute carrier family 17 (sodium phosphate), member 3 (SLC17A3);
• solute carrier family 19 (folate transporter), member 1 (SLC19A1);
• solute carrier family 2 (facilitated glucose transporter), member 1 (SLC2A1);
• solute carrier family 23 (nucleobase transporters), member 2 (SLC23A2);
• solute carrier family 25 (mitochondrial carrier;
• oxoglutarate carrier), member 11 (SLC25A11);
• solute carrier family 31 (copper transporters), member 2 (SLC31A2);
• solute carrier family 4, anion exchanger, member 2 (erythrocyte membrane protein band 3-like 1) (SLC4A2);
• solute carrier family 4, sodium bicarbonate cotransporter, member 8 (SLC4A8);
• solute carrier family 7 (cationic amino acid transporter, y+ system), member 5 (SLC7A5);
• solute carrier family 7 (cationic amino acid transporter, y+ system), member 6 (SLC7A6);
• solute carrier family 9 (sodium/hydrogen exchanger), isoform 6 (SLC9A6);
• somatic cytochrome c (HCS);
• SON DNA binding protein (SON);
• son of sevenless (Drosophila) homolog 1 (SOS1);
• sorcin (SRI);
• sortilin 1 (SORT1);
• sortilin-related receptor, L (DLR class) A repeats-containing (SORL1);
• sorting nexin 1 (SNX1);
• sorting nexin 2 (SNX2);
• Sp3 transcription factor (SP3);
• special AT-rich sequence binding protein 1 (binds to nuclear matrix/scaffold-associating DNA's) (SATB1);
• speckle-type POZ protein (SPOP);
• spectrin SH3 domain binding protein 1 (SSH3BP1);
• Spectrin, alpha, non-erythrocytic 1 (alpha-fodrin) (SPTAN1);
• spermidine/spermine N1-acetyltransferase (SAT);
• spermine synthase (SMS);
• SPF31 (SPF31);
• sphingomyelin phosphodiesterase 1, acid lysosomal (acid sphingomyelinase) (SMPD1);
• spinocerebellar ataxia 1 (olivopontocerebellar ataxia 1, autosomal dominant, ataxin 1) (SCA1);
• spinocerebellar ataxia 2 (olivopontocerebellar ataxia 2, autosomal dominant, ataxin 2) (SCA2);
• spinocerebellar ataxia 7 (olivopontocerebellar atrophy with retinal degeneration) (SCA7);
• spliceosome associated protein (SAP 145);
• splicing factor (CC1.3) (CC1.3);
• splicing factor SRp40-1 (SRp40);
• splicing factor, arginine/serine-rich 11 (SFRS11);
• splicing factor, arginine/serine-rich 7 (35 kD) (SFRS7);
• Src-like-adapter (SLA);
• stannin (SNN);
• STAT induced STAT inhibitor 3 (SSI-3);
• STE20-like kinase 3 (MST-3);
• step 11 splicing factor SLU7 (SLU7);
• steroid sulfatase;
• steroid sulfatase (microsomal), arylsulfatase C, isozyme S (STS);
• sterol carrier protein 2 (SCP2);
• sterol O-acyltransferase (acyl-Coenzyme A:
• cholesterol acyltransferase) 1 (SOAT1);
• stimulated trans-acting factor (50 kDa) (STAF50);
• Stromal antigen 2 (STAG2);
• stromal interaction molecule 1 (STIM1);
• structure specific recognition protein 1 (SSRP1);
• succinate dehydrogenase complex, subunit A, flavoprotein (Fp) (SDHA);
• succinate dehydrogenase complex, subunit B, iron sulfur (Ip) (SDHB);
• succinate dehydrogenase complex, subunit C, integral membrane protein, 15 kD (SDHC);
• succinate dehydrogenase complex, subunit D, Integral membrane protein (SDHD);
• succinate-CoA ligase, GDP-forming, beta subunit (SUCLG2);
• succinyl CoA synthetase;
• sudD (suppressor of bimD6, Aspergillus nidulans) homolog (SUDD);
• sulfotransferase family 1A, phenol-preferring, member 1 (SULT1A1);
• superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) (SOD1);
• superoxide dismutase 2, mitochondrial (SOD2);
• supervillin (SVIL);
• suppression of tumorigenicity 5 (ST5);
• suppressor of K+ transport defect 1 (SKD1);
• suppressor of Ty (S. cerevisiae) 3 homolog (SUPT3H);
• suppressor of Ty (S. cerevisiae) 4 homolog 1 (SUPT4H1);
• suppressor of Ty (S. cerevisiae) 5 homolog (SUPT5H);
• suppressor of Ty (S. cerevisiae) 6 homolog (SUPT6H);
• suppressor of variegation 3-9 (Drosophila) homolog 1 (SUV39H1);
• survival of motor neuron 1, telomeric (SMN1);
• SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2);
• SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 (SMARCA4);
• SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily c, member 2 (SMARCC2);
• SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1 (SMARCE1);
• synaptobrevin-like 1 (SYBL1);
• synaptosomal-associated protein, 23 kD (SNAP23);
• syndecan binding protein (syntenin) (SDCBP);
• synovial sarcoma, translocated to X chromosome (SSXT);
• syntaxin 16;
• syntaxin 3A (STX3A);
• syntaxin 6 (STX6);
• SYNTAXIN BINDING PROTEIN 3 (UNC-18 HOMOLOG 3) (UNC-18C);
• syntaxin-16C;
• SYT interacting protein (SIP);
• T cell activation, increased late expression (TACTILE);
• T cell receptor V alpha gene segment V-alpha-7 (clone IGRa11);
• T cell receptor V alpha gene segment V-alpha-w27;
• T3 receptor-associating cofactor-1;
• tafazzin (cardiomyopathy, dilated 3A (X-linked);
• endocardial fibroelastosis 2;
• Barth syndrome) (TAZ);
• tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase (TNKS);
• TAR DNA-binding protein-43;
• Tat interactive protein (60 kD) (TIP60);
• TATA box binding protein (TBP)-associated factor, RNA polymerase II, F, 55 kD (TAF2F);
• TATA box binding protein (TBP)-associated factor, RNA polymerase II, G, 32 kD (TAF2G);
• TATA box binding protein (TBP)-associated factor, RNA polymerase II, I, 28 kD (TAF2I);
• Taxi (human T-cell leukemia virus type I) binding protein 1 (TAX1BP1);
• TBP-associated factor 172 (TAF-172);
• T-cell death-associated gene 8 (TDAG8);
• T-cell leukemia/lymphoma 1A (TCL1A);
• T-cell receptor (delta D2-J1-region) (clone K3B);
• T-cell receptor delta gene D2-J1-region, clone K3B;
• T-cell receptor germline beta chain gene V-region (V) V-beta-MT1-1;
• T-cell receptor germline beta-chain gene J2.1 exon;
• T-cell receptor germline delta-chain D-J region;
• T-cell receptor interacting molecule (TRIM) protein;
• T-cell receptor rearranged delta-chain, V-region (V-delta 3-J);
• T-cell receptor, alpha (V,D,J,C) (TCRA);
• T-cell receptor, beta cluster (TCRB);
• T-cell receptor, delta (V,D,J,C) (TCRD);
• T-cell, immune regulator 1 (TCIRG1);
• TCF-1 mRNA for T cell factor 1;
• TCR eta=T cell receptor (eta-exon);
• TCR V Beta 13.2;
• TERA;
• testis enhanced gene transcript (TEGT);
• tetracycline transporter-like protein (TETRAN);
• tetratricopeptide repeat domain 1 (TTC1);
• tetratricopeptide repeat domain 2 (TTC2);
• tetratricopeptide repeat domain 3 (TTC3);
• TGFB1-induced anti-apoptotic factor 1 (TIAF1);
• thioredoxin reductase 1 (TXNRD1);
• threonyl-tRNA synthetase (TARS);
• thrombin inhibitor;
• thrombospondin 1 (THBS1);
• thromboxane A synthase 1 (platelet, cytochrome P450, subfamily V) (TBXAZ1);
• thymidine kinase 2, mitochondrial (TK2);
• thymidylate kinase (CDC8);
• thymine-DNA glycosylase (TDG);
• Thymosin, beta 10 (TMSB10);
• thymosin, beta 4, X chromosome (TMSB4X);
• thyroid autoantigen 70 kD (Ku antigen) (G22P1);
• thyroid hormone receptor coactivating protein (SMAP);
• thyroid hormone receptor interactor 7 (TRIP7);
• thyroid hormone receptor interactor 8r (TRIP8);
• thyroid hormone receptor-associated protein, 230 kDa subunit (TRAP230);
• thyroid receptor interacting protein 15 (TRIP15);
• TI-227H;
• TIA1 cytotoxic granule-associated RNA-binding protein (TIA1);
• tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor) (TIMP1);
• tissue inhibitor of metalloproteinase 2 (TIMP2);
• tissue specific transplantation antigen P35B (TSTA3);
• titin (TTN);
• TNF receptor-associated factor 2 (TRAF2);
• TNF receptor-associated factor 3 (TRAF3);
• toll-like receptor 1 (TLR1);
• toll-like receptor 2 (TLR2);
• toll-like receptor 4 (TLR4);
• toll-like receptor 5 (TILR5);
• topoisomerase (DNA) I (TOP1);
• topoisomerase (DNA) II beta (180 kD) (TOP2B);
• topoisomerase (DNA) III beta (TOP3B);
• TR3beta;
• TRAF family member-associated NF-kB activator (TANK);
• transaldolase 1 (TALDO1);
• transaldolase-related protein;
• transcobalamin II (TCII);
• transcription elongation factor B (SIII), polypeptide 1-like (TCEB1L);
• transcription elongation factor B (SIII), polypeptide 3 (110 kD, elongin A) (TCEB3);
• transcription factor 12 (HTF4, helix-loop-helix transcription factors 4) (TCF12);
• transcription factor 17 (TCF17);
• transcription factor 4 (TCR4);
• transcription factor 6-like 1 (mitochondrial transcription factor 1-like) (TCF6L1);
• transcription factor 7-like 2 (T-cell specific, HMG-box) (TCF7L2);
• transcription factor binding to IGHM enhancer 3 (TFE3;
• transcription factor IL-4 Stat;
• transcription factor TFIID;
• transcriptional adaptor 2 (ADA2, yeast, homolog)-like (TADA2L);
• transducin (beta)-like 1 (TBL1);
• transducin-like enhancer of split 3, homolog of Drosophila E (sp1) (TLE3);
• Transformation/transcription domain-associated protein (TRRAP);
• transformation-sensitive, transforming growth factor beta-stimulated protein TSC-22 (TSC22);
• transforming growth factor, beta receptor III (betaglycan, 300 kD) (TGFBR3);
• transforming growth factor, beta-induced, 68 kD (TGFBI);
• transgelin 2 (TAGLN2);
• trans-Golgi network protein (46, 48, 51 kD isoforms) (TGN51);
• transient receptor potential channel 1 (TRPC1);
• transketolase (Wernicke-Korsakoff syndrome) (TKT);
• translation factor sui1 homolog (GC20);
• translin (TSN);
• translin-associated factor X (TSNAX);
• transmembrane glycoprotein (A33);
• transmembrane protein (63 kD), endoplasmic reticulum/Golgi intermediate compartment (P63);
• transmembrane protein 1 (TMEM2);
• transmembrane trafficking protein (TMP21);
• transporter 1, ABC (ATP binding cassette) (TAP1);
• Treacher Collins-Franceschetti syndrome 1 (TCOF1);
• triosephosphate isomerase 1 (TPI1);
• tropomyosin;
• tropomyosin 4 (TPM4);
• TRPM-2 protein;
• tryptophan rich basic protein (WRB);
• tryptophanyl-tRNA synthetase (WARS);
• Ts translation elongation factor, mitochondrial (TSFM);
• topoisomerase (DNA) II beta (180 kD);
• Tu translation elongation factor, mitochondrial (TUFM);
• tuberous sclerosis 1 (TSC1);
• tuberous sclerosis 2 (TSC2);
• tubulin, alpha 1 (testis specific) (TUBA1);
• tubulin, alpha, ubiquitous (K-ALPHA-1);
• tubulin-specific chaperone c (TBCC);
• tumor necrosis factor (ligand) superfamily, member 10 (TNFSF10);
• tumor necrosis factor (ligand) superfamily, member 13 (TNFSF13);
• tumor necrosis factor (ligand) superfamily, member 14 (TNFSF14);
• tumor necrosis factor (ligand) superfamily, member 6 (TNFSF6);
• tumor necrosis factor (ligand) superfamily, member 8 (TNFSF8);
• tumor necrosis factor alpha-inducible cellular protein containing leucine zipper domains (FIP2);
• Tumor necrosis factor receptor superfamily member 7 (TNFRSF7);
• tumor necrosis factor receptor superfamily, member 10b (TNFRSF10B);
• tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain (TNFRSF10C);
• tumor necrosis factor receptor superfamily, member 12 (translocating chain-association membrane protein) (TNFRSF12);
• tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator) (TNFRSF14);
• tumor necrosis factor receptor superfamily, member 1B (TNFRSF1B);
• tumor necrosis factor receptor superfamily, member 6 (TNFRSF6);
• tumor necrosis factor receptor superfamily, member 7 (TNFRSF7);
• tumor necrosis factor, alpha-induced protein 2 (TNFAIP2);
• tumor necrosis factor, alpha-induced protein 3 (TNFAIP3);
• tumor protein 53-binding protein, 1 (TP53BP1);
• tumor protein p53 (L1-Fraumeni syndrome) (TP53);
• Tumor protein p53-binding protein (TP53BPL);
• tumor protein, translationally-controlled 1 (TPT1);
• tumor rejection antigen (gp96) 1 (TRA1);
• tumorous imaginal discs (Drosophila) homolog (TID1);
• TXK tyrosine kinase (TXK);
• type II integral membrane protein (NKG2-E);
• TYRO protein tyrosine kinase binding protein (TYROBP);
• tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta polypeptide (YWHAB);
• tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide (YWHAZ);
• Tyrosine kinase 2 (TYK2);
• tyrosyl-tRNA synthetase (YARS);
• U1 small nuclear RNA;
• U2 (RNU2) small nuclear RNA auxillary factor 1 (non-standard symbol) (U2AF1);
• U22 snoRNA host gene (UHG);
• U4/U6-associated RNA splicing factor (HPRP3P);
• U49 small nuclear RNA;
• U5 snRNP-specific protein (220 kD), ortholog of S. cerevisiae Prp8p (PRP8);
• U5 snRNP-specific protein, 116 kD (U5-116 KD);
• U5 snRNP-specific protein, 200 kDa (DEXH RNA helicase family) (U5-200-KD);
• Uba80 mRNA for ubiquitin;
• ubiquinol-cytochrome c reductase (6.4 kD) subunit (UQCR);
• ubiquitin A-52 residue ribosomal protein fusion product 1 (UBA52);
• ubiquitin activating enzyme E1-like protein (GSA7);
• ubiquitin C (UBC);
• ubiquitin carboxyl-terminal esterase L3 (ubiquitin thiolesterase) (UCHL3);
• ubiquitin fusion degradation 1-like (UFD1L);
• ubiquitin protein ligase E3A (human papilloma virus E6-associated protein, Angelman syndrome) (UBE3A);
• ubiquitin specific protease 10 (USP10);
• ubiquitin specific protease 11 (USP11);
• ubiquitin specific protease 15 (USP15);
• ubiquitin specific protease 19 (USP19);
• ubiquitin specific protease 4 (proto-oncogene) (USP4);
• ubiquitin specific protease 7 (herpes virus-associated) (USP7);
• ubiquitin specific protease 8 (USP8);
• ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing) (UBE1);
• ubiquitin-activating enzyme E1, like (UBE1L);
• UBIQUITIN-BINDING PROTEIN P62;
• phosphotyrosine independent ligand for the Lck SH2 domain p62 (P62);
• ubiquitin-conjugating enzyme E2 variant 1 (UBE2V1);
• ubiquitin-conjugating enzyme E2 variant 2 (UBE2V2);
• ubiquitin-conjugating enzyme E2B (RAD6 homolog) (UBE2B);
• ubiquitin-conjugating enzyme E2G 2 (homologous to yeast UBC7) (UBE2G2);
• ubiquitin-conjugating enzyme E2H (homologous to yeast UBC8) (UBE2H);
• ubiquitin-conjugating enzyme E2 L1 (UBE2L1);
• ubiquitin-conjugating enzyme E2L 3 (UBE2L3);
• ubiquitin-conjugating enzyme E2L 6 (UBE2L6);
• ubiquitin-like 1 (sentrin) (UBL1);
• UDP-N-acetyl-alpha-D galactosamine:polypeptide N-acetylgalactosaminyltransferase 2 (GalNAc-T2) (GALNT2);
• unactive progesterone receptor, 23 Kd (P23);
• unconventional myosin-ID (MYO1F);
• uncoupling protein homolog (UCPH);
• uppressor of Ty (S. cerevisiae) 6 homolog;
• upregulated by 1,25-dihydroxyvitamin D-3 (VDUP1);
• upstream binding factor (hUBF);
• UV radiation resistance associated gene (UVRAG);
• vacuolar proton-ATPase, subunit D;
• V-ATPase, subunit D (ATP6DV);
• v-akt murine thymoma viral oncogene homolog 1 (AKT1);
• Vanin 2 (VNN2);
• vasodilator-stimulated phosphoprotein (VASP);
• vav 1 oncogene (VAV1);
• vav 2 oncogene (VAV2);
• v-crk avian sarcoma virus CT10 oncogene homolog (CRK);
• v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 (ERBB3);
• Vesicle-associated membrane protein 1 (synaptobrevin 1) (VAMP1);
• vesicle-associated membrane protein 3 (cellubrevin) (VAMP3);
• v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS);
• villin 2 (ezrin) (VIL2);
• villin-like protein;
• vimentin (VIM);
• vinculin (VCL);
• vitamin A responsive;
• cytoskeleton related (JWA);
• v-jun avian sarcoma virus 17 oncogene homolog (JUN);
• v-myb avian myeloblastosis viral oncogene homolog (MYB);
• voltage-dependent anion channel 1 (VDAC1);
• voltage-dependent anion channel 3 (VDAC3);
• von Hippel-Lindau syndrome (VHL);
• v-raf murine sarcoma 3611 viral oncogene homolog 1 (ARAF1);
• v-raf-1 murine leukemia viral oncogene homolog 1 (RAF1);
• v-ral simian leukemia viral oncogene homolog B (ras related;
• GTP binding protein) (RALB);
• V-rel avian reticuloendotheliosis viral oncogene homolog A (nuclear factor of kappa light polypeptide gene enhancer in B-cells 3 (p65)) (RELA);
• v-yes-1 Yamaguchi sarcoma viral related oncogene homolog (LYN);
• WD repeat domain 1 (WDR1);
• WD-repeat protein (HAN11);
• Williams-Beuren syndrome chromosome region 1 (WBSCR1);
• Wiskott-Aldrich syndrome protein interacting protein (WASPIP);
• X (inactive)-specific transcript (XIST);
• xeroderma pigmentosum, complementation group C (XPC);
• XIAP associated factor-1;
• XIB;
• X-linked anhidroitic ectodermal dysplasia;
• X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining;
• Ku autoantigen, 80 kD) (XRCC5);
• XRP2 protein;
• yeloid differentiation primary response gene (88) (MYD88);
• zeta-chain (TCR) associated protein kinase (70 kD) (ZAP70);
• zinc finger protein (Hs.47371);
• zinc finger protein (Hs.78765);
• zinc finger protein 10 (KOX 1) (ZNF10);
• zinc finger protein 136 (clone pHZ-20) (ZNF136);
• zinc finger protein 140 (clone pHZ-39) (ZNF140);
• zinc finger protein 143 (clone pHZ-1) (ZNF143);
• zinc finger protein 148 (pHZ-52) (ZNF148);
• zinc finger protein 173 (ZNF173);
• zinc finger protein 198 (ZNF198);
• zinc finger protein 200 (ZNF200);
• zinc finger protein 207 (ZNF207);
• zinc finger protein 216 (ZNF216);
• zinc finger protein 217 (ZNF217);
• zinc finger protein 230 (ZNF230);
• Zinc finger protein 239 (ANF239);
• zinc finger protein 261 (ZNF261);
• zinc finger protein 262 (ANF262);
• zinc finger protein 263 (ZNF263);
• zinc finger protein 264 (ZNF264);
• zinc finger protein 42 (myeloid-specific retinoic cid-responsive) (ZNF42);
• zinc finger protein 45 (a Kruppel-associated box (KRAB) domain polypeptide) (ZNF45);
• zinc finger protein 76 (expressed in testis) (ZNF76);
• zinc finger protein 84 (HPF2) (ZNF84);
• zinc finger protein 85 (ZNF85));
• zinc finger protein 9 (ZNF9);
• zinc finger protein C2H2-25 (ZNF25);
• zinc finger protein clone L3-4;
• zinc finger protein homologous to Zfp-36 in mouse (ZFP36);
• zinc finger protein HZF4;
• zinc finger protein RIZ;
• zinc finger protein, subfamily 1A, 1 (Ikaros) (LYF1);
• zinc finger transcriptional regulator (GOS24);
• zinc-finger helicase (hZFH);
• Zn-15 related zinc finger protein (rlf);
• ZNF80-linked ERV9 long terminal repeat;
• ZW10 (Drosophila) homolog, centromere/kinetochore protein (ZW10);
• and zyxin (ZYX);
• thereby identifying at least one potential marker for differentiating between different body states.